Qué es la dieta de la zona - Referencias bibliográficas

• Sears, B. The Zone. New York: ReganBooks, 1995.

• Oates, J. A. “The 1982 Nobel prize in physiology or medicine.” Science 218:765–768 (1982).
• Sears, B. The Zone. New York: ReganBooks, 1995.
• Sears, B. TheAnti-Aging Zone. New York: ReganBooks, 1999.
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.

• Braunwald, E. “Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and applications.” N Engl J Med 337:1360–1369 (1997).
• McGeer, P. L., M. Shulzer, and E. G. McGeer. “Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiological studies.” Neurology 47:425–432 (1996).
• Morris, M. C., D. A. Evans, J. L. Bienias, C. C. Tangney, D. A. Bennett, R. S. Wilson, N. Aggarwal, and J. Schneider. “Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease.” Arch Neurol 60:940–966 (2003).
• Moghadasian, M. H. “Experimental atherosclerosis. A historical overview.” Life Sci70:855–865 (2002).
• Olser, W. Lectures on Angina Pectoris and Allied States.New York: Appleton, 1897.
• Ross, R. “Atherosclerosis is an inflammatory disease.” N Engl J Med 340:115–126 (1999).
• Wolfe, M. M., R. D. Lichtenstein, and G. Singh. “Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs.” N Engl J Med 340:1888–1889 (1999).
• Yudkin, J. S., C. D. A. Stehouwer, J. J. Emeis, and S. W. Coppack. “C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction—a potential role for cytokines originating from adipose tissue?” Arterioscler Thromb Vasc Biol 19:972–978 (1999).

• Sears, B. The Zone. New York: ReganBooks, 1995.
• Sears, B. TheAnti-Aging Zone. New York: ReganBooks, 1999.
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.

• Adams, P., S. Lawson, A. Sanigorski, and A. J. Sinclair. “Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.” Lipids 31:S157-S161 (1996).
• Boizel, R., P. Y. Behhamou, B. Lardy, F. Laporte, T. Foulon, and S. Halimi. “Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels.” Diabetes Care 23:1679–1685 (2000).
• Campbell, B., T. Badrick, R. Flatman, and D. Kanowshi. “Limited clinical utility of high-sensitivity plasma C-reactive protein assays.” Ann Clin Biochem 39:85–88 (2002).
• Campbell, B., R. Flatman, T. Badrick, and D. Kanowshi. “Problems with high sensitivity C-reactive protein.” Clin Chem49:201 (2003).
• Conquer, J. A., M. C. Tierney, J. Zecevic, W. J. Bettger, and R. H. Fisher. “Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment.” Lipids 35:1305–1312 (2000).
• Danesh, J., J. G. Wheeler, G. M. Hirschfield, G. Eiriksdottir, A. Remley, G. D. Lowe, M. B. Pepys, and J. Gudnason. “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.” N Engl J Med 350:1387–1397 (2004).
• DeLongeril, M., S. Renaud, N. Mamelle, P. Salen, J. L. Martin, I, Monjaud, J. Guidollet, P. Touboul, and J. Delaye. “Mediterranean alpha-linolenic acid rich diet in secondary prevention of coronary heart disease.” Lancet 343:1454–1459 (1994).
• DeLongeril, M., P. Salen, J. L. Martin, I. Monjaud, J. Delaye, and N. Mamelle. “Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.” Circulation 99:779–785 (1999).
• Deron, S. J. C-reactive Protein.Chicago: Contemporary Books, 2003.
• Feng, D., R. P. Tracy, I. Lipinska, J. Murillo, C. McKenna, and G. H. Tofler.“Effect of short-term aspirin use on C-reactive protein.” J Thromb Throm-bolysis 9:37–41 (2000).
• Feldman, M., I. Jialal, S. Devaraj, and B. Cryer. “Effects of low-dose aspirin onserum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.” J AmColl Cardiol37:2036–2041 (2001).
• Gaziano, J. M., C. H. Hennekens, C. J. O’Donnell, J. L. Breslow, and J. E. Buring. “Fasting triglycerides, high-density lipoproteins and risk of myocardial infarction.” Circulation 96:2520–2525 (1997).
• Iso, H., S. Sato, A. R. Falsm, T. Shimamoto, A. Terao, R. G. Munger, A. Kitamure, M. Konishi, M. Iida, and Y. Komachi. “Serum fatty acids and fish intake in rual Japanese, urban Japanese, Japanese American and Caucasian American men.” Int J Epidemiol 18:374–381 (1989).
• Jeppesen, J., H. O. Hein, P. Suadicani, and F. Gyntelberg. “Low triglycerides-highhigh-density lipoprotein cholesterol and risk of ischemic heart disease.” ArchIntern Med161:361–366 (2001).
• Kagawa, Y., M., Nishizawa, M. Suzuki, T. Miyatake, T. Hamamoto, K. Goto, E. Motonaga, H. Izumikawa, H. Hirata, and A. Ebihara. “Eicosapolyenoic acid of serum lipids of Japanese islanders with low incidence of cardiovascular diseases.” J Nutr Sci Vitaminol 28:441–453 (1982).
• Kluft, C. and M. P. M. de Maat. “Genetics of C-reactive protein.” ArteriosclerThromb Vasc Biol 23:1956–1959 (2003).
• Kromann, N. and A. Green. “Epidemiological studies in Upernavik district, Greenland.” Acta Med Scand 208:401–406 (1974).
• Laidlaw, M. and B. J. Holub. “Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women.” Am J Clin Nutr 77:37–42 (2003).
• Lamarche, B., A. Tchernot, P. Mauriege, B. Cantin, G. R. Gagenais, P. J. Lupien, and J-P. Despres. “Fasting insulin and apolipoprotein B levels and low-density particle size as risk factors for ischemic heart disease.” JAMA 279:1965–1971 (1998).
• Maes, M. “Fatty acid composition in major depression: decreased n-3 fractions in cholesterol esters and increased C20:n6/C20:5n3 ratio in cholesterol ester and phospholipids.” J Affect Dis 38:35–46 (1996).
• Maes, M., A. Christophe, J. Delanghe, C. Altamura, H. Neels, and H. Y. Meltzer. “Lowered omega-3 polyunsaturated fatty acids in serum phospholpids and cholesteryl esters of depressed patients.” Pscyhiatry Res 85:275–291 (1999).
• Nakamura, T., A. Azuma, T. Kuribayashi, H. Sugihara, S. Okuda, and M. Nakagawa. “Serum fatty acid levels, dietary style and coronary heart in three neighbouring areas in Japan.” Br J Nutr 89:267–272 (2003).
• Nordvik, I., K. M. Myhr, H. Nyland, and K. S. Bjerve. “Effect of dietary adviceand n-3 supplementation in newly diagnosed MS patients.” Acta NeurolScand 102:143–149 (2000).
• Pedesen, H. S., G. Mulvad, K. N. Seidelin, G. T. Malcom, and D. A. Doudreau. “N-3 fatty acids as a risk marker for haemorrhagic stroke.” Lancet 353:812–813 (1999).
• Pirro, M., J. Bergeron, G. R. Dagenais, P-M. Bernard, B. Cantin, J-P. Depres, and B. Lamarche. “Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levelsinmen.” Arch Intern Med161:2474–2480 (2001).
• Ridker, P. M. “High-sensitivity C-reactive protein.” Circulation 103:1813–1818 (2001).
• Ridker, P. M., M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens. “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.” N Engl J Med 336:973–979 (1996).
• Ridker, P. M., N. Fifai, M. J. Stampfer, and C. H. Hennekens. “Plasma concentration of interleukin-6 and the risk of future myocardinal infarction among apparently healthy men.” Circulation 101:1767–1772 (2000).
• Ridker, P. M., C. H. Hennekens, J. E. Buring, and N. Rifai. “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.” New Engl J Med 42:836–843 (2000).
• Ridker, P. M., N. Rifai, M. A. Pfeffer, F. M. Sacks, L. A. Moye, S. Goldman, G. C.Flaker, E. Braunwald. “Inflammation, pravastatin, and the risk of coronaryevents after myocardial infarction in patients with average cholesterollevels. Cholesterol and Recurrent Events (CARE ) Investigators.” Circula-tion 98:839–44 (1998).
• Rifai, N. and P. M. Ridker. “High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.” Clin Chem 47:403–411 (2001).
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002. Stevens, L. J. and J. Burgess. “Omega-3 fatty acids in boys with behavior, learning, and health problems.” Physiology Behavior 59:915–920 (1996).
• Stevens, L. J., S. S. Zentall, J. L. Deck, M. L. Abate, B. A. Watkins, S. A. Lipp, and J. R. Burgess. “Essential fatty acid metabolism in boys with attention deficit hyperactivity disorder.” Am J Clin Nutr 62:761–768 (1995).
• Takeda, T., S. Hoshida, M. Nishino, J. Tanouchi, K. Otsu, and M. Hori. “Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels.” Atherosclerosis 169:155–188 (2003).
• Tall, A. R. “C-reactive protein reassessed.” N Engl J Med 350:1450–1452 (2004).
• Upritchard, J. E., W. H. Sutherland, and J. I. Mann. “Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes.” Diabetes Care 23:733–738 (2000).
• Yamada, T., J. P. Strong, T. Ishii, T. Ueno, M. Koyama, H. Wagayama, A. Shimizu, T. Sakai, G. T. Malcom, and M. A. Guzman. “Atherosclerosis and omega-3 fatty acids in the populations of a fishing village and a farming village in Japan.” Atherosclerosis153:469–481 (2000).
• Yeni-Komshian, H., M. Caratoni, F. Abbasi, and G. M. Reaven. “Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers.” Diabetes Care 23:171–175 (2000).

• Astrup, P. A., D. T., Meinert Larsen, and A. Harper. “Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss?” Lancet 364:897–899 (2004).
• Bell, S. J. and B. Sears. “Low glycemic load diets: impact on obesity and chronic diseases.” Crit Rev Food Sci Nutr 43:357–377 (2003).
• Bell, S. J. and B. Sears. “A proposal for a new national diet: a low glycemic loaddiet with a unique macronutrient composition.” Metabolic Syndrome andRelated Disorders 1:199–200 (2003).
• Flegal, K. M., M. D. Carroll, C. L. Ogden, and C. L. Johnson. “Prevalence and trends in obesity among US adults, 1999–2000.” JAMA 288:1723–1727 (2002).
• Foster-Powell, K., S. H. Holt, J. C. Brand-Miller. “International table of glycemic index and glycemic load values: 2002.” Am J Clin Nutr 76:5–56 (2002).
• Jenkins, D. J., T. M. Wolever, R. H. Taylor, H. Barker, H. Fielden, J. M. Baldwin, A. C. Bowling, H. C. Newman, A. L. Jenkins, and D. V. Goff. “Glycemicindex of foods: a physiological basis for carbohydrate exchange.” Am JClin Nutr 34:362–366 (1981).
• Leeds, A. R. “Glycemic index and heart disease.” Am J Clin Nutr 76:286S 289S (2002).
• Liu, S., J. E. Manson, J. E. Buring, M. J. Stampfer, W. C. Willett, and P. M. Ridker. “Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women.” Am J Clin Nutr 75:492–498 (2002).
• Liu, S., J. E. Manson, M. J. Stampfer, M. D. Holmes, F. B. Hu, S. E. Hankinson,and W. C. Willett. “Dietary glycemic load assessed by food-frequencyquestionnaire in relation to plasma high-density-lipoprotein cholesteroland fasting plasma triacylglycerols in postmenopausal women.” Am J ClinNutr 73:560–566 (2001).
• Liu, S., W. C. Willett, M. J. Stampfer, F. B. Hu, M. Franz, L. Sampson, C. H. Hennekens, and J. E. Manson. “A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women.” Am J Clin Nutr 71:1455–1461 (2002).
• Ludwig, D. S. “The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease.” JAMA 287:2414–2423 (2002).
• Ludwig, D. S., J. A. Majzoub, A. Al-Zahrani, G. E. Dallal, I. Blanco, and S. B. Roberts. “High glycemic index foods, overeating, and obesity.” Pediatrics 103:E26 (1999).
• Mokdad, A. H., E. S. Ford, B. A. Bowman, W. H. Dietz, F. Vinicor, V. S. Bales, and J. S. Marks. “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.” JAMA 289:76–79 (2003).
• Mokdad, A. H., E. S. Ford, B. A. Bowman, D. E. Nelson, M. M. Engelgau, F. Vini-cor, and J. S. Marks. “Diabetes trends in the U.S.” 1990–1998.” DiabetesCare 23:1278–1283 (2000).
• Ogden, C. L., K. M. Flegal, M. D. Carroll, and C. L. Johnson. “Prevalence and trends in overweight among US children and adolescents, 1999–2000.” JAMA 288:1728–32 (2002).
• Roberts, S. B. “High-glycemic index foods, hunger, and obesity: is there a connection?” Nutr Rev 58:163–169 (2000).
• Salmeron, J., J. E. Manson, M. J. Stampfer, G. A. Colditz, A. L. Wing, and W. C. Willett. “Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women.” JAMA 277:472–477 (1997).
• Sears, B. The Zone. New York: ReganBooks, 1995.
• Sears, B. Mastering the Zone. New York, ReganBooks, 1997.
• Sears, B. AWeek in the Zone. New York: ReganBooks, 2000.
• Sears, B. and S. J. Bell. “The Zone Diet: an anti-inflammatory, low glycemic-load diet.” Metabolic Syndrome and Related Disorders2:24–38 (2004).
• Sears, B. and L. Sears. Zone Meals in Seconds. New York: ReganBooks, 2002.
• Willett, W., J. Manson and S. Liu. “Glycemic index, glycemic load, and risk of type 2 diabetes.” Am J Clin Nutr 76:274S-280S (2002).

• Sears, B. The Zone. New York: ReganBooks, 1995.
• Sears, B. Mastering the Zone. New York, ReganBooks, 1997.
• Sears B. Zone Perfect Meals in Minutes. New York: ReganBooks, 1998.
• Sears B. Zone Food Blocks. New York: ReganBooks, 1998.
• Sears B. Top 100 Zone Foods. New York: ReganBooks, 1999.
• Sears, B. AWeek in the Zone. New York: ReganBooks, 2000.
• Sears, B. and L. Sears. Zone Meals in Seconds. New York: ReganBooks, 2004.

• Arisawa, K., T. Matsummura, C. Tohyama, H. Saito, M. Hagai, M. Morita, and T. Suzuki. “Fish intake, plasma omega-3 polyunsaturated fatty acids, and polychlorinated dibenzo-p-dioxins/polychlorinated dibenzo-furans and co planar polychlorinated biphenyls in the blood of the Japanese population.” Int Arch Occup Environ Health 76:205–215 (2003).
• Pedesen, H. S., G. Mulvad, K. N. Seidelin, G. T. Malcom, and D. A. Doudreau. “N-3 fatty acids as a risk marker for haemorrhagic stroke.” Lancet 353:812–813 (1999).
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.
• Zuijdgeest-van Leeuwen, S. D., P. C. Dagnelie, T. Rietveld, J. W. O. van den Berg, and J. H. P. Wilson. “Incorporation and washout of rally administered n-3 fatty acid ethyl esters in different plasma lipid fracions.” Brit J Nutr 82:481–488 (1999).

• Albert, M. A., R. J. Glynn, and P. M. Ridker. “Alcohol consumption and plasma concentration of C-reactive protein.” Circulation 107:443–447 (2003). DeLongeril, M., S. Renaud, N. Mamelle, P. Salen, J. L. Martin, I. Monjaud, J.
• Guidollet, P. Touboul, and J. Delaye. “Mediterranean alpha-linolenic acid rich diet in secondary prevention of coronary heart disease.” Lancet 343:1454–1459 (1994).
• DeLongeril, M., P. Salen, J. L. Martin, I. Monjaud, J. Delaye, and N. Mamelle. “Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.” Circulation 99:779–785 (1999).
• GISSI-Prevenzione Investigators. “Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.” Lancet 354:447–455 (1999).
• Higdon, J. V., S. H. Du, Y. S. Lee, T. Wu, and R. C. Wander. “Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate.” J Lipid Res 42:407–418 (2001).
• Horrocks, L. A. and Y. K. Yeo. “Health benefits of docosahexaenoic acid (DHA).” Pharmacol Res 40:211–225 (1999).
• Jacobs, E. J., C. J. Connell, A. V. Patel, A. Chao, C. Rodriguez, J. Seymour, M. L. McCullough, E. E. Calle, and M. J. Thun. “Vitamin C and vitamin E supplement use and colorectal cancer mortality in a large American Cancer Society cohort.” Cancer Epidemiol Biomarkers Prev 10:17–23 (2001).
• Kangasaho, M., M. Hillbom, M. Kaste, and H. Vapaatalo. “Effects of ethanol intoxication and hangover on plasma levels of thromboxane B2 and 6 keto-prostaglandin F1 alpha and on thromboxane B2 formation by platelets in man.” Thromb Haemost 48:232- 234 (1982).
• Lee, S. H. and I. A. Blair. “Vitamin C–induced decomposition of lipid hydroperoxides to endogenous genotoxins.” Science 292:2083–2086 (2001). Leitzmann, M. F., M. J. Stampfer, D. S. Michaud, K. Augustsson, G. C. Colditz, W. C. Willett, and E. L. Giovannucci. “Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer.” Am J Clin Nutr 80:204–216 (2004).
• Lonn, E., S. Yusuf, B. Hoogwerf, J. Pogue, Q. Yi, B. Zinman, J. Bosch, G. Dagenais, J. F. Mann, and H. C. Gerstein. “Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.” Diabetes Care 25:1919–1927 (2002).
• Omenn, G. S., G. E. Goodman, M. D. Thornquist, J. Balmes, M. R. Cullen, A. Glass, J. P. Keogh, F. L. Meyskens, B. Valanis, J. H. Williams, S. Barnhart, M. G. Cherniack, C. A. Brodkin, and S. Hammar. “Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.” J Natl Cancer Inst 88:1550–1559 (1996).
• Stephens, N. G., A. Parsons, P. M. Schofield, F. Kelly, K. Cheeseman, and M. J. Mitchinson. “Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).” Lancet 347:781–786 (1996).
• Tornwall, M. E., J. Virtamo, P. A. Korhonen, M. J. Virtanen, P. R. Taylor, D. Albanes, and J. K. Huttunen. “Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study.” Eur Heart J 25:1171–1178 (2004).

• Calder, P. C. and P. Yaqoob. “Glutamine and the immune system.” Amino Acids 17:227–241 (1999).
• Church, T. S., Y. J. Cheng, C. P. Earnest, C. E. Barlow, L. W. Gibbons, E. L. Priest, and S. N. Blair. “Exercise capacity and body composition as predictors of mortality among men with diabetes.” Diabetes Care 27:83–88 (2004).
• Farrell, S. W., L. Braun, C. E. Barlow, Y. J. Cheng, and S. N. Blair. “The relation of body mass index, cardiorespiratory fitness, and all-cause mortality in women.” Obesity Res 10:417–423 (2002).
• Horner, P. J. and F. H. Gage. “Regenerating the damaged central nervous system.” Nature 407:963–970
• Lee, C. D., S. N. Blair, and A. S. Jackson. “Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men.” Am J Clin Nutr 69:373–380 (1999).
• Neeper, S. A., F. Gomez-Pinilla, J. Choi, and C. W. Cotman. “Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain.” Brain Res726:49–56 (1996).
• Newsholme, P. “Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?” J Nutr S131:2515S-2522S (2001).
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.
• Wojtaszewski, J. R. P., B. F. Hansen, J. Gade, B. Kiena, J. F. Markuna, L. J. Goodyear, and E. A. Richter. “Insulin signaling and insulin sensitivity after exercise in human skeletal muscle.” Diabetes 49:325–331 (2000).

• Benson, H. The Relaxation Response. New York: William Morrow, 1975.Carrington, P. The Book of Mediation.Boston: Element Books, 1998.Hamazaki, T., M. Itomura, S. Sawazaki, and Y. Nagao. “Anti-stress effects of
• DHA.” Biofactors 13:41–45 (2000).
• Homer, H., D. Packan, and R. M. Sapolsky. “Glucocorticoids inhibit glucose transort in cultured hippocampal neurons and glia.” Neuroendocrinology 52:57–63 (1990).
• Kamei, T., Y. Toriumi, H. Kimura, S. Ohno, H. Kumano, and K. Kimura. “Decrease in serum cortisol during yoga exercise is correlated with alpha wave activation.” Percept Mot Skills 90:1027–1032 (2000).
• MacLean, C. R., K. G. Walton, S. R. Wenneberg, D. K. Levitsky, J. P. Man-darino, R. Waziri, S. L. Hillis, and R. H. Schneider. “Effects of the Transcen-dental Meditation program on adaptive mechanisms: changes in hormonelevels and responses to stress after 4 months of practice.” Psychoneu-roendocrinology 22:277–295 (1997).
• Maes, M., A. Christophe, E. Bosmans, A. Lin, and H. Neels. “In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress.” Psychiatry 47:910–920 (2000).
• Maier, S. F. and L. R. Watkins. “Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition.” Psychol Rev 105:83–107 (1998).
• Sears, B. TheAnti-Aging Zone. New York: ReganBooks, 1999.
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.
• Spiegel, K., R. Leproult, and E. Van Cauter. “Impact of sleep debt on metabolic and endocrine function.” Lancet 354:1435–1439 (1999).
• Spolsky, R. M. Stress,the Aging Brain, and the Mechanisms of Neuron Death. Cambridge, MA: MIT Press, 1992.
• Spolsky, R. M., D. R. Packan, and W. W. Vale. “Glucocorticoid toxicity in the hippocampus.” Brain Res 453:367–371 (1988).
• Sudsuang, R., V. Chentanez, and K. Veluvan. “Effect of Buddhist meditation on serum cortisol and total protein levels, blood pressure, pulse rate, lung volume and reaction time.” Physiol Behav 50:543–548 (1991).
• Talbott, S. and W. Kramer. The Cortisol Connection. Berkeley, CA: Hunter House, 2002.
• Vgontzas, A. N., E. Zoumakis, E. O. Bixler, H. M. Lin, H. Follett, A. Kales, and G. P. Chrousos. “Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines.” J Clin Endocrinol Metab 89:2119–2126 (2004).
• Wilson, J. L. Adrenal Fatigue.Petaluma, CA: Smart Publications, 2001.

• Barham, J. B., M. B. Edens, A. N. Fonteh, M. M. Johnson, L. Easter, and F. H. Chilton. “Addition of eicosapentaenoic acid to gamma-linolenic-acid supplemented diets prevents serum arachidonic acid accumulation in humans.” J Nutr 130:1925–1931 (2000).
• Brenner, R. R. “Nutrition and hormonal factors influencing desaturation of essential fatty acids.” Prog Lipid Res 20:41–48 (1982).
• Burr, G. O. and M. R. Burr. “A new deficiency disease produced by rigid exclusion of fat from the diet.” J Biol Chem 82:345–367 (1929).
• Chapkin, R. S., S. D. Somer, and K. L. Erickson. “Dietary manipulation of macrophage phospholipids classes: selective increase in dihomo gamma linolenic acid.” Lipids23:776–770 (1988).
• Chavali, S. R. and R. A. Forse. “Decreased production of interleukin-6 and prostaglandin E2 associated with inhibition of delta-5 desaturation of omega 6 fatty acids in mice fed safflower oil diets supplemented with sesamol.” Prostaglandins Leukot Essent Fatty Acids 61:347–352 (1999).
• Cho, H. P., M. Nakamura, and S. D. Clarke. “Cloning, expression, and fatty acid regulation of human delta 5 desaturase.” J Biol Chem 274:37335–37399 (1999).
• Clarke, S. D. “Polyunsaturated fatty acid regulation of gene transcription: a mechanism to improve energy balance and insulin resistance.” Br J Nutr 83:S59-S66 (2000).
• Connor, W. E. “Importance of n-3 fatty acids in health and disease.” Am JClin Nutr 71:S171S-S175 (2000).
• Conquer, J. A. and B. J. Holub. “Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores.” Lipids 32:341–345 (1997).
• El Boustani, S., J. E. Gausse, B. Descomps, L. Monnier, F. Mendy, and A. Crastes de Paulet. “Direct in vivo characterization of the delta-5 desaturase activity in humans by deuterium labeling: effect of insulin.” Metabolism 38:315-3321 (1989).
• Ferreria, S. H., S. Moncada, and J. R. Vane. “Indomethacin and aspirin abolish prostaglandin release from the spleen.” Natur New Bio 231:237–239 (1971).
• Garg, M. L., A. B. R. Thomson, and M. T. Clandinin. “Effect of dietary cholesterol and/or omega-3 fatty acids on lipid composition and delta 5-desaturase activity of rat liver microsomes.” J Nutr 118:661–668 (1998).
• Hill, E. G., S. B. Johnson, L. D. Lawson, M. M. Mahfouz, and R. T. Holman. “Perturbation of the metabolism of essential fatty acids by dietary partially hydrogenated vegetable oil.” Proc Natl Acad Sci U S A 79:953–957 (1982).
• Oates, J. A. “The 1982 Nobel prize in physiology or medicine.” Science 218:765–768 (1982).
• Pelikonova, T., M. Kohout, J. Base, Z. Stefka, L. Kovar, L. Kerdova, and J. Valek. “Effect of acute hyperinsulinemia on fatty acid composition of serum lipid in non-insulin dependent diabetics and healthy men.” ClinChem Acta 203:329–337 (1991).
• Phinney, S. “Potential risk of prolonged gamma-linolenic acid use.” Ann InternMed120:692 (1994).
• Robertson, R. P., D. J. Gavarenski, D. Porte, and E. L. Bierman. “Inhibition of in vivo insulin secretion by prostaglandin E1.” J Clin Invest 54:310–315 (1974).
• Sears, B. The Zone. New York: ReganBooks, 1995.
• Sears, B. TheAnti-Aging Zone. New York: ReganBooks, 1999.
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.
• Serhan, C. N. “Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: anupdate and role in anti-inflammation and pro-resolution.” ProstaglandinsOther Lipid Mediat 69:433–455 (2002).
• Shimizu, S., K. Akimoto, Y. Shinmen, H. Kawashima, M. Sugano, and H. Yamada. “Sesamin is a potent and specific inhibitor of delta 5 desaturase in polyunsaturated fatty acid biosynthesis.” Lipids 26:512–516 (1991).
• Smith, D. L., A. L. Willis, N. Nguyen, D. Conner, S. Zahedi, and J. Fulks. “Eskimo plasma constituents, dihomo gamma linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid inhibit the release of atherogenic mitogens.” Lipids 24:70–75 (1989).
• Stone, K. J., A. L. Willis, M. Hurt, S. J. Kirtland, P. B. A. Kernof, and G. F. McNichol. “The metabolism of dihomo gamma linolenic acid in man.” Lipids 14:174–180 (1979).
• Von Euler, U. S. “On specific vasodilating and plain muscle stimulating substances from accessory genital glands in men and certain animals (prostaglandins and vesiglandin).” J Physiol (London) 88:213–234 (1936).
• Willis, A. L. Handbook of Eicosanoids, Prostaglandins, and Related Lipids. Boca Raton: CRC Press, 1987.
• Yam, D., B. Elitaz, B. Eliraz, and M. Elliot. “Diet and disease: the Israeli paradox: possible dangers of a high omega-6 polyunsaturated fatty acid diet.” Isr J Med Sci32:1134–1143 (1996).

• Babcok, T., W. S. Helton, and N. J. Espat. “Eicosapentaenoic acid: an anti inflammatory omega-3 fat with potential clinical applications.” Nutrition 16:1116–1118 (2000).
• Bazan, N. G. and R. L. Flower. “Lipid signals in pain control.” Nature 420:135–138 (2002).
• Bechoua, S., M. Dubois, G. Nemoz, P. Chapy, E. Vericel, M. Lagarde, and A. F. Prigent. “Very low dietary intake of n-3 fatty acids affects the immune function of healthy elderly people.” Lipids 34:S143 (1999).
• Bleumink, G. S., J. Feenstra, M. C. M. J. Sturkenboom, and B. H. C. Stricker. “Nonsteroidal anti-inflammatory drugs and heart failure.” Drugs 63:525–534 (2003).
• Blok, W. L., M. B. Katan, and J. W. van der Meer. “Modulation of inflammation and cytokine production by dietary (n-3) fatty acids.” J Nutr 126:1515–1533 (1996).
• Calder, P. C. “n-3 polyunsaturated fatty acids and cytokine production in health and disease.” Ann Nutr Metab 41:203–234 (1997).
• Calder, P. C. “n-3 polyunsaturated fatty acids, inflammation and immunity.” Nutr Res 21:309–341 (2001).
• Calder, P. C. “Dietary modification of inflammation with lipids.” Proc Nutr Soc 61:345–358 (2002).
• Endres, S. “Messengers and mediators: interactions among lipids,eicosanoids, and cytokines.” Am J Clin Nutr 57:798S-800S (1993).
• Endres, S. “n-3 polyunsaturated fatty acids and human cytokine synthesis.” Lipids 31:S239–242 (1996).
• Endres, S., R. Ghorbani, V. E. Kelley, K. Georgilis, G. Lonnemann, J. W. van der Meer, J. G. Cannon, T. S. Rogers, M. S. Klempner, and P. C. Weber. “The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells.” N Engl J Med 320:265–271 (1989).
• Endres, S., R. Lorenz, and K. Loeschke. “Lipid treatment of inflammatory bowel disease.” Curr Opin Clin Nutr Metab Care 2:117–20 (1999).
• Endres, S. and von Schacky, C. “n-3 polyunsaturated fatty acids and human cytokine synthesis.” Curr Opin Lipidol 7:48–52. (1996).
• Hong, S., K. Gronert, P. R. Devchand, R. L. Moussignac, and C. N. Serhan. “Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autocoids in anti-inflammation.” J Biol Chem 278:14677–14687 (2003).
• Jozsef, L., C. Zouki, N. A. Petasis, C. N. Serhan, and J. G. Filep. “Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitriete formation, NF kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes.” Proc Natl Acad Sci U S A 99:13266–13271 (2002).
• Lawrence, T., D. A. Willoughby, and D. W. Gilroy. “Anti-inflammatory lipidmediators and insights into the resolution of inflammation.” Nature RevImmunol 2:787–795 (2002).
• Levy, B., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. “Lipid mediatorclass switching during acute inflammation: signals in resolution.” NatureImmunol 2:612–619 (2001).
• Lo, C. J., K. C. Chiu, M. Fu, R. Lo, and S. Helton. “Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappaB activity.” J Surg Res 82:216–221 (1999).
• Meydani, S. N. “Effect of n-3 polyunsaturated fatty acid on cytokine produc-tion and their biological action.” Nutrition12:S8–14 (1996).
• Perretti, M., N. Chiang, M. La, I. M. Fierro, S. Marullo, S. J. Getting, E. Solito, and C. N. Serhan. “Endogenous lipid- and peptide derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.” Nature Med 9:1296–1302 (2002).
• Serhan, C. N. “Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: anupdate and role in anti-inflammation and pro-resolution.” ProstaglandinsOther Lipid Mediat 69:433–455 (2002).
• Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R. L. Moussignac. “Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits intiated by aspirin treatment that counter proinflammation signals.” J Exp Med 196:1025–1037 (2002).
• Sperling, R. I. “The effects of dietary n-3 polyunsaturated fatty acids on neutrophils.” Proc Nutr Soc 57:527–534 (1998).
• Tak, P. P., and G. S. Firestein. “NF-kappaB: a key role inflammatory diseases.” JClin Invest107:7–11 (2001).
• Teitelbaum, J. E., and W. Allan Walker. “The role of omega-3 fatty acids in intestinal inflammation.” J Nutr Biochem 12:21–32 (2001).
• Tracey, K. J. “The inflammatory reflex.” Nature 420:853–859 (2002).
• Trowbridge, H. O. and R. C. Emling. Inflammation.Chicago: Quintessence Publishing, 1997.
• Van Dyke, T. E., and C. N. Serhan. “Resolution of inflammation.” J Dental Res 82:82–90 (2003).
• Zurier, R. B. “Eicosanoids and inflammation.” In Prostaglandins in Clinical Prac-tice, ed. W. D. Watkins, M. B. Peterson, and J. R. Flectcher, pp. 79–96.New York: Raven Press, 1989.

• Allison, D. B., R. Zannolli, M. S. Faith, M. Heo, A. Pietrobelli, T. B. Van Itallie, F. X. Pi-Sunyer, and S. B. Heymsfield. “Weight loss increases and fat lossdecreases all-cause mortality rate.” Int J Obes 23:603–611 (1999).American Diabetes Association. “Economic costs of diabetes in the U.S. in2002.” Diabetes Care 26:917–932 (2003).
• Bloomgarden, Z. T. “Cardiovascular disease and diabetes.” Diabetes Care 26:230–237 (2003).
• Bloomgarden, Z. T. “Inflammation and insulin resistance.” Diabetes Care 26:1922–1926 (2003).
• Borkman, M., L. H. Storlien, D. A. Pan, A. B. Jenkins, D. J. Chisholm, and L. V. Campbell. “The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phopholipids.” N Engl J Med 328:911–917 (1993).
• Botion, L. M. and A. Green. “Long-term regulation of lipolysis and hormone sensitive lipase by insulin and glucose.” Diabetes 48:1691–1697 (1999).
• Brandes, J. “Insulin induced overeating in the rat.” Physiol Rev 18:1095–1102 (1977).
• Challem, J., B. Berkson, and M. D. Smith. Syndrome X. New York: John Wileyand Sons, 2000.
• Coste, T. C., A. Gerbi, P. Vague, G. Pieroni, and D. Raccah. “Neuroprotective effect of docosahexaenoic acid–enriched phospholipids in experimental diabetic neuropathy.” Diabetes 52:2578–2585 (2003).
• Cshe, K., G. Winkler, Z. Melczer, and E. Baranyi. “The role of tumor necrosis factor resistance in obesity and insulin resistance.” Diabetologia 43:525 (2000).
• Despres, J-P., I. Lemieux, and D. Prudhomme. “Treatment of obesity: need to focus on high risk abdominally obese patients.” Brit J Med 322:716–720 (2001).
• Drewnowski, A. “Nutrition transition and global dietary trends.” Nutrition 16:486–487 (2000).
• Ebbeling, C. B., M. M. Leidig, K. B. Sinclair, J. P. Hangen, and D. S. Ludwig. “Areduced glycemic load diet in the treatment of adolescent obesity.” ArchPediatr Adoles Med 157:773–779 (2003).
• Fernandez-Real, J-M., M. Vayreda, C. Richart, C. Gutierrez, M. Broch, J. Ven-drell, and W. Ricart. “Circulating interleukin-6 levels, blood pressure, andinsulin sensitivity in apparently healthy men and women.” JClin EndocrinolMetab 86:1154–1159 (2001).
• Festa, A., R. D’Agostino, G. Howard, L. Mykkanen, R. P. Tracy, and S. M. Haffner. “Chronic subclinical inflammation as part of the insulin resistance syndrome.” Circulation102:42–47 (2000).
• Freeman, D. J., J. Norrie, M. J. Caslake, A. Gaw, I. Ford, G. D. O. Lowe, D. O’Reilly, C. J. Packard, and N. Sattar. “C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland coronary prevention study.” Diabetes 51:1596–1600 (2002).
• Freeth, A., V. Udupi, R. Basile, and A. Green. “Prolonged treatment with prostaglandin E1 increases rate of lipolysis in rat adipocytes.” Life Sci 73:393–401 (2003).
• Friedman, A. N., L. G. Hunsicker, J. Selhub, and A. G. Bostom. “Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy.” Atherosclerosis 172:121–125 (2004).
• Folsom, A. R., J. Ma, P. G. McGovern, and H. Eckfeldt. “Relationship betweenplasma phospholipid saturated fatty acids and hyperinsulinemia.” Metabo-lism 45:223–228 (1996).
• Fontaine, K. R., D. T. Redden, C. Wang, A. O. Westfall, and D. B. Allison. “Years of life lost due to obesity.” JAMA 289:187–193 (2003).
• Ford, E. S., W. H. Giles, and W. H. Dietz. “Prevalence of the metabolic syndrome among US adults.” JAMA 287:356–359 (2002).
• Ford, E. S., W. H. Giles, G. L. Myers, N. Rifai, P. M. Ridker, and D. M. Mannino. “C-reactive protein concentration distribution among US children and young adults.” Clin Chem 49:1353–1357 (2003).
• Fruhbeck, G., J. Gomez-Ambrosi, F. J. Muruzabal, and M. A. Burrell. “The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation.” Am J Physiol Endocrinol Metab 280:E827–E847 (2001).
• Gannon, M. C., F. Q. Nuttall, A. Saeed, K. Jordan, and H. Hoover. “An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes.” Am J Clin Nutr 78:734–741 (2003).
• Garg, A. “High-monounsaturated fat diets for patients with diabetes mellitus: a meta analysis.” Am J Clin Nutr 67:577S–582S (1998).
• Gerbi, A., J-M. Maixent, J-L. Ansaldi, M. Pierlovisi, T. Coste, J-F. Pelissier, P. Vague, and D. Raccah. “Fish oil supplementation prevents diabetes induced nerve conduction velocity and neuroanatomical changes in rats.” J Nutr 129:207–213 (1999).
• Gerbi, A., J-M. Maxient, O. Barbey, I. Jamme, M. Pierlovishi, T. Coste, G. Pieroni, A. Nouvelot, P. Vague, and D. Raccah. “Neuroprotective effect of fish oil in diabetic neuropathy.” Lipids34:S93-S94 (1999).
• Haemmerle, G., R. Zimmermann, and R. Zechner. “Letting lipids go: hormone sensitive lipase.” Cur Opin Lipidol14:289–297 (2003).
• Hasler, G., D. J. Buysse, R. Klaghofer, A. Gamma, V. Ajdacic, D. Eich, W. Rossler, and J. Angst. “The association between short sleep duration and obesity in young adults: a 13-year prospective study.” Sleep 15:661–666 (2004).
• Hauner, H. “Insulin resistance and the metabolic syndrome—a challenge of the new millennium.” Eur J Clin Nutr56:S25–S29 (2002).
• Herkner, H., N. Klein, C. Joukhadar, E. Lackner, H. Langenberger, M. Frossard, C. Bieglmayer, O. Wagner, M. Roden, and M. Muller. “Transcapillary insulin transfer in human skeletal muscle.” Eur J Clin Invest33:141–146 (2003).
• Hostens, K., D. Pavlovic, Y. Zambre, Z. Ling, C. van Schravendijk, D. L. Eizirik, and D. G. Pipeleers. “Exposure of human islets to cytokines can result in the disproportionately elevated proinsulin release.” J Clin Invest 104:67–72 (1999).
• Hotamisligil, G. S. “Mechanisms of TNF induced insulin resistance.” Exp ClinEndocrinol Diabetes 107:119–125 (1999).
• Hotamisligil, G. S., P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman. “Increase adipose tissue expression of tumor necrosis factor in human obesity and insulin resistance.” JClin Invest95:2409–2415 (1995).
• Jansen, M. D. “Cytokine regulation of lipolysis in humans.” J Clin EndocrinolMetab 88:3003–3004 (2003).
• Javisalo, M. J., A. Harmoinen, M. Hakanen, U. Paakunainen, J. Vilkari, J. Hari-ala, T. Lehtimaki, O. Simell, and O. T. Raitakari. “Elevated C-reactive pro-tein levels and early arterial changes in healthy children.” ArteriosclerThromb Vasc Biol 22:1323–1328 (2002).
• Jensen, T., S. Stender, K. Goldstein, G. Holmer, and T. Deckert. “Partial nor-malization by dietary cod liver oil of increased microvascular albumin leak-age in patients with insulin-dependent diabetes and albuminuria.” N Engl JMed 321:1572–1577 (1989).
• Kahn, B. B. and J. S. Flier. “Obesity and insulin resistance.” J Clin Invest 106:473–481 (2000).
• Katan, M. B., S. M. Grundy, and W. C. Willett. “Should a low-fat, high-carbohy-drate diet be recommended for everyone? Beyond low-fat diets.” N Engl JMed 337:563–567 (1997).
• Kern, P. A., S. Ranganathan, C. Li, L. Wood, and G. Ranganathan. “Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.” Am J Physiol Endocrinol Metab 280:E745–E751 (2001).
• Khan, L. K. and B. A. Bowman. “Obesity: a major global public health problem.” Ann Rev Nutr 19:xii–xvii (1999).
• Kim, S. and N. Moustaid-Moussa. “Secretory, endocrine andautocrine/paracrine function of the adipocyte.” JNutr130:3110S–3115S(2000).
• Krogh-Madsen, R., P. Plomgaaard, Keller Pernlle, C. Keller, and B. K. Pedersen.“Insulin stimulates interleukin-6 and tumor necrosis factor-alpha geneexpression in human subcutaneous adipose tissue.” Am J PhysiolEndocrinol Metab 286:E234–E238 (2004).
• Kyselova, P., M. Zourek, Z. Rusavy, L. Trefil, and J. Racek. “Hyperinsulinemia and oxidative stress.” Physiol Res 51:591–595 (2002).
• Lehrke, M. and M. A. Lazar. “Inflamed about obesity.” Nature Med 10:126–127 (2004).
• Luo, J., S. W. Rizkalla, J. Boillot, C. Alamowitch, H. Chaib, F. Bruzzo, N. Desplanque, A. M. Dalix, G. Durand, and G. Slama. “Dietary (n-3) polyunsaturated fatty acids improve adipocyte insulin action and glucose metabolism in insulin-resistant rats: relationship to membrane fatty acids.” J Nutr 126:1951–1958 (1996).
• Marett, A. “Molecular mechanisms of inflammation in obesity-linked insulin resistance.” Int J Obesity 27:S46–S48 (2003).
• Markovic, T. P., A. C. Fleury, L. V. Campbell, L. A. Simons, S. Balasubramanian, D. J. Chisholm, and A. B. Jenkins. “Benefical effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes.” Diabetes Care21:695–700 (1998).
• Markovic, T. P., A. B. Jenkins, L. V. Campbell, S. M. Furler, E. W. Kragen, and D. J. Chisholm. “The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM.” Diabetes Care 21:687–694 (1998).
• McLaughlin, T., F. Abbasi, C. Lemendola, L. Liang, G. Reaven, P. Schaaf, and P. Reaven. “Differentiation between obesity and insulin resistance in the association with C-reactive protein.” Circulation 106:2908–2912 (2002).
• Mobbs, C. V. “Genetic influences on glucose neurotoxicity, aging and diabetes: a possible role for glucose hysteresis.” Genetica 91:239–253 (1993).
• Mokdad, A. H., E. S. Ford, B. A. Bowman, W. H. Dietz, F. Vinicor, V. S. Bales, and J. S. Marks. “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.” JAMA 289:76–79 (2003).
• Mokdad, A. H., E. S. Ford, B. A. Bowman, D. E. Nelson, M. M. Engelgau, F. Vini-cor, and J. S. Marks. “Diabetes trends in the U.S.” 1990–1998.” DiabetesCare 23:1278–1283 (2000).
• Mokdad, A. H., M. K. Serdula, W. H. Dietz, B. A. Bowman, J. S. Marks, and J. P.Kaplan. “The spread of the obesity epidemic in the United States.1991–1998.” JAMA282:1519–1522 (1999).
• Montague, C. T., and S. O’Rahilly. “The perils of portliness: causes and consequences of visceral adiposity.” Diabetes 49:883–888 (2000).
• Montori, V. M., A. Farmer, P. C. Wollan, and S. F. Dinneen. “Fish oil supple-mentation in type 2 diabetes: a quantitative systematic review.” DiabetesCare 23:1407–1415. (2000).
• Moran, T. H. “Cholecystokinin and satiety.” Nutrition 16:858–865 (2000).
• Mori, T. A., D. Q. Bao, V. Burke, I. B. Puddey, G. F. Watts, L. J. Beilin. “Dietaryfish as a major component of a weight-loss diet: effect on serum lipids,glucose, and insulin metabolism in overweight hypertensive subjects.” AmJClin Nutr70:817–825 (1999).
• Narayan, K. M. V., J. P. Boyle, T. J. Thompson, S. W. Sorensen, and D. F. Williamson. “Lifetime risk for diabetes mellitus in the United States.” JAMA 290:1884–1890 (2003).
• Nichols, G. A., H. S. Glauber, and J. B. Brown. “Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis.” Diabetes Care 23:1654–1659 (2000).
• Nuttall, F. Q., M. C. Gannon, A. Saeed, K. Jordan, and H. Hoover. “The metabolic response of subjects with type 2 diabetes to a high-protein, weight maintenance diet.” J Clin Endocrinol Metab 88:3577–3583 (2003).
• Park, Y-W., S. Zhu, L. Palaniappan, S. Heshka, M. R. Carethon, and S. Heymsfield. “The metabolic syndrome.” Arch Intern Med 163:427–436 (2003).
• Peraldi, P. and B. Spegelman. “TNF and insulin resistance: summary and future prospects.” Mol Cell Biochem 182:169–175 (1998).
• Pittas, A. G., N. A. Joseph, and A. S. Greenberg. “Adipocytokines and insulin resistance.” J Clin Endocrinol Metab 89:447–452 (2004).
• Pradeepa, R. and V. Mohan. “The changing scenario of the diabetes epidemic: implications for India.” Indian J Med Res116:121–132 (2002).
• Qi, C. and P. H. Pekala. “Tumor necrosis factor alpha induced insulin resistance in adipocytes.” Proc Soc Exp Biol Med 223:128–135 (2000).
• Raheja, B. S., S. M. Sakidot, R. B. Phatak, and M. B. Rao. “Significance of the N-6/N-3 ratio for insulin action in diabetics.” Ann N Y Acad Sci 983:258–271 (1993).
• Rask-Madsen, C., H. Dominguez, N. Ihlemann, T. Hermann, L. Lober, and C. Torp-Pedersen. “Tumor necrosis factor-alpha inhibits insulin’s stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans.” Circulation 108:1815–1821 (2003).
• Reaven, G. M. and A. Laws. Insulin Resistance. The Metabolic Syndrome X. Totowa, NJ: Humana Press, 1999.
• Rivellese, A., A. Maffettone, C. Iovine, L. Di Marino, G. Annuzzi, M. Mancini,and G. Riccardi. “Long-term effects of fish oil on insulin resistance andplasma lipoprotein in NIDDM patients with hypertriglyceridemia.” DiabetesCare 19:1207–1213 (1996).
• Roberts, S. B. “High glycemic index foods, hunger, and obesity: is there a connection.” Nutr Rev 58:163–169 (2000).
• Rosenbloom, A. L., J. R. Joe, R. S. Young, and W. E. Winter. “Emerging epidemic of type 2 diabetes in youth.” Diabetes Care 22:345–354 (1999).
• Salmeron, J., A. Ascherio, E. B. Rimm, G. A. Colditz, D. Spiegelman, D. J. Jenkins, M. J. Stampfer, A. L. Wing, and W. C. Willett. “Dietary fiber, glycemic load, and risk of NIDDM in men.” Diabetes Care 20:545–550 (1997).
• Salmeron, J., J. E. Manson, and W. C. Willett. “Dietary fiber, glycemic load, and risk of non-insulin dependent diabetes mellitus in women.” JAMA 277:472–477 (1997).
• Samaras, K., and L. V. Campbell. “Increasing incidence of type 2 diabetes in the third millennium.” Diabetes Care 23:441–442 (2000).
• Sears, B. The Zone. New York: ReganBooks, 1995.
• Sears, B. TheAnti-Aging Zone. New York: ReganBooks, 1999.
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.
• Seidell, J. C. “Obesity, insulin resistance and diabetes-a worldwide epidemic.” Brit J Nutr83:S5–S8 (2000).
• Sirtori, C. R., G. Crepaldi, E. Manzato, M. Mancini, A. Rivellese, R. Paolett, F. Pazzucconi, F. Pamparana, and E. Stragliotto. “One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance. Reduced triglyceridemia, total cholesterol and increased HDL-C with glycemic alterations.” Atherosclerosis 137:419–427 (1998).
• Skov, A. R., S. Toubro, B. Renn, L. Holm, and A. Astrup. “Randomized trial on protein vs. carbohydrate in ad libitum fat reduced diet for the treatment of obesity.” Int J Obes 23:528–536 (1999).
• Steinberg, H. O., H. Chaker, R. Learning, A. Johnson, G. Brechtel, and A. D. Baron. “Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.” J Clin Invest 97:2601–2610 (1996).
• Stene, L. C., J. Ulriksen, P. Magnus, and G. Joner. “Use of cod liver oil during pregnancy associated with lower risk of type 1 diabetes in the offspring.” Diabetologia 42:1093–1098 (2000).
• Storlien, L. H., A. B. Jenkins, D. J. Chisholm, W. S. Pascoe, S. Khour, and E. W. Kragen. “Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglycerides and omega-3 fatty acids in muscle phospholipids.” Diabetes 40:280–289 (1991).
• Storlien, L. H., E. W. Kraegen, D. J. Chisholm, G. L. Ford, D. G. Bruce, and W. S. Pascoe. “Fish oil prevents insulin resistance induced by high-fat feedingin rats.” Science237:885–888 (1987).Unger, R. H. “Glucagon and the insulin-glucagon ratio in diabetes and othercatabolic illnesses.” Diabetes20:834–838 (1971).Unger, R. H. and P. J. Lefebvre. Glucagon: Molecular Physiology, Clinical andTherapeutic Implications.Oxford: Pergamon Press, 1972.
• Vessby, B., S. Tengblad, and H. Lithell. “Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men.” Diabetologia 37:1044–1050 (1994).
• Vinik, A. I., T. S. Park, K. B. Stansberry, and G. L. Pittenger. “Diabetic neuropathies.” Diabetologia 43:957–973 (2000).
• Visser, M. “Higher levels of inflammation in obese children.” Nutrition 17:480–484 (2001).
• Visser, M., L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris. “Elevated C-reactive protein levels in overweight and obese adults.” JAMA 282:2131–2315 (1999).
• Willett, W. C. “Dietary fat and obesity: an unconvincing relation.” Am J Clin Nutr68:1149–1150 (1998).Willett, W. C. “Is dietary fat a major source of body fat?” Am J Clin Nutr67:556S–562S (1998).Yudkin, J. S., M. Kumari, S. E. Humphries, and V. Modamed-Ali. “Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?” Ather-osclerosis 148:209–214 (2000).
• Yudkin, J. S., C. D. A. Stehouwer, J. J. Emeis, and S. W. Coppack. “C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction—a potential role for cytokines originating from adipose tissue?” Arterioscler Thromb Vasc Biol 19:972–978 (1999).

• Albert, C. M., H. Campos, M. J. Stampfer, P. M. Ridker, J. E. Manson, W. C. Willett, and J. Ma. “Blood levels of long-chain n-3 fatty acids and risk of sud- den death.” N Engl J Med 346:1113–1118 (2002).
• Albert, C. M., C. H. Hennekens, C. I. O’Donnel, U. A. Ajani, V. J. Carey, and W. C. Willett. “Fish consumption and risk of sudden cardiac death.” JAMA 279:23–28 (1998).
• Anderson, J. L., and J. B. Muhlestein. “Restenosis after coronary intervention: narrowing C-reactive protein’s prognostic potential?” Am J Med 115:147–149 (2003).
• Anderson, K. M., W. P. Castelli, and D. Levy. “Cholesterol and mortality: 30 years of follow-up from the Framingham Study.” JAMA 257:2176–2180 (1987).
• Angerer, P. and C. von Schacky. “N-3 polyunsaturated fatty acids and cardiovascular system.” Curr Opin Lipidol 11:57–63 (2000). Ascherio, A., C. H. Hennekens, J. E. Buring, C. Master, M. J. Stampfer, and W. C. Willett. “Trans fatty acid intake and risk of myocardial infarction.” Cir-culation 89:94–101 (1994).
• Ascherio, A., E. B. Rimm, M. J. Stampfer, E. L. Giovannucci, and W. C. Willett. “Dietary intake of marine n-3 fatty acids, fish intake, and risk of coronary heart disease among men.” N Engl J Med 332:977–982 (1995).
• Ascherio, A. and W. C. Willett. “Health effects of trans fatty acids.” Am J ClinNutr 66:1006S-1010S (1997).Austin, M. A. “Plasma triglcyceride and coronary heart disease.” ArteriosclerThromb Vasc Biol 11:2–14 (1991).Austin, M. A., J. L. Breslow, C. H. Hennekens, J. E. Buring, W. C. Willett, and R. M. Krauss. “Low density lipoprotein subclass patterns and risk of myocardinal infarction.” JAMA 260:1917–1920 (1988). Bang, H., O. Dyerberg, and A. B. Nielsen. “Plasma lipid and lipoprotein pattern in Greenlandic west-coast Eskimos.” Lancet i:1143–1145 (1971). Bao, W., S. R. Srinivasan, and G. S. Berenson. “Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults.” Circulation 93:54–59 (1996).
• Bataile, R., and B. Klein. “C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo.” Arthritis Rheum 35:982–983 (1992).
• Bellamy, C. M., P. M. Schofield, E. B. Faragher, and D. R. Ramsdale. “Can supplementation of diet with omega-3 polyunsaturated fatty acids reduce coronary angioplasty restenosis rate?” Eur Heart J 13:1626–1631 (1992).
• Bellosta, S., N. Ferri, F. Bernini, R. Paoletti, and A. Corsini. “Non-lipid related effects of statins.” Ann Med32:164–176 (2000).
• Billman, G. E., J. X. Kang, and A. Leaf. “Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs.” Circulation 99:2452–2457 (1999).
• Black, H. R. “The coronary artery disease paradox. The role of hyperinsuline-mia and insulin resistance and implications for therapy.” J CardiovascularPharmacol 15:26S–38S (1990).
• Boizel, R., P. Y. Behhamou, B. Lardy, F. Laporte, T. Foulon, and S. Halimi. “Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels.” Diabetes Care 23:1679–1685 (2000).
• Bowles, M. H., D. Klonis, T. G. Plavac, B. Gonzales, D. A. Francisco, R. W. Roberts, G. R. Boxberger, L. R. Poliner, and J. P. Galichia. “EPA in the prevention of restenois post PTCA.” Angiology 42:187–194 (1991).
• Braunwald, E. “Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and applications.” N Engl J Med 337:1360–1369 (1997).
• Burr, M. L. “Lessons from the story of n-3 fatty acids.” Am J Clin Nutr 71:397S–398S (2000).
• Burr, M. L., A. M. Fehily, J. F. Gilbert, S. Rogers, R. M. Holliday, P. M. Sweetnam, P. C. Elwood, and N. M. Deadman. “Effects of changes in fat, fish, and fibre intakes on the death and myocardial reinfarction: diet and reinfarction trial (DART).” Lancet ii:757–761 (1989).
• Busse, R., and I. Flemining. “Endothelial dysfunction in atherosclerosis.” J Vasc Res 33:181–194 (1996).
• Campbell, B., T. Badrick, R. Flatman, and D. Kanowshi. “Limited clinical utility of high-sensitivity plasma C-reactive protein assays.” Ann Clin Biochem 39:85–88 (2002).
• Campbell, B., R. Flatman, T. Badrick, and D. Kanowshi. “Problems with high sensitivity C-reactive protein.” Clin Chem49:201 (2003).
• Carantoni, M., F. Abbasi, F. Warmerdan, M. Klebanov, P. W. Wang, Y. D. Chen, S. Azhar, and G. M. Reaven. “Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers.” Arte-rioscler Thromb Vasc Biol 18:762–767 (1998).
• Chan, D. C., G. F. Watts, T. A. Mori, P. H. R. Barrett, L. J. Beilin, and T. G. Red- grave. “Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.” Eur J Clin Invest32:429–436 (2002).
• Christensen, J. H., M. S. Christensen, J. Dyerberf, and E. B. Scmidt. “Heart rate variability and fatty acid content of blood cell membranes: a dose response study with n-3 fatty acids.” Am J Clin Nutr 70:331–337 (1999).
• Cleland, S. J., N. Sattar, J. R. Petrie, N. G. Forouhi, H. L. Elliott,and J. M. C. Connell. “Endothelial dysfunction as a possible link between C-reactive protein and cardiovascular disease.” Clin Sci 98:531–535 (2000).
• Coresh, J., P. O. Kwiterovich, and H. H. Smith. “Association of plasma triglyceride concentration and LDL particle diameter, density, and chemico-compostion with premature coronary artery disease.” J Lipid Res 34:1687–1697 (1993).
• Corti, M-C., J. M. Guraink, M. E. Saliva, T. Harris, T. S. Field, R. B. Wallace, L. F. Berkman, T. E. Seeman, R. J. Glynn, C. H. Hennekens, and R. J. Havlik. “HDL cholesterol predicts coronary heart disease mortality in older persons.” JAMA 274:539–544 (1995).
• Cullen, P., S. Lorkowski, H. Schulte, U. Seedorf, and G. Assmann. “Inflammation in atherosclerosis, not yet for a paradigm shift?” Curr Opin Lipidol 14:325–328 (2003).
• Davidson, J. and D. Rotondo. “Lipid metabolism: inflammatory-immune response in atherosclerosis.” Curr Opin Lipidol 14:337–339 (2003).
• Daviglus, M. L., M. Stamler, A. J. Orencia, A. R. Dyer, K. Liu, P. Greenland, M. K. Walsh, D. Morris, and R. B. Shekelle. “Fish consumption and the 30-yearrisk of myocardial infarction.” NEngl J Med336:1046–1053 (1997).Davignon, J. and J. S. Cohn. “Triglycerides: a risk factor for coronary heartdisease.” Atherosclerosis 124:S57-S64 (1996).
• De Caterina, R., M. I. Cybulsk, S. K. Clinton, M. A. Gimbrone, and P. Libby. “The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory protein in human endothelial cells.” Arterioscler Thromb Vasc Biol14:1829–1836 (1994).
• De Caterina, R. and A. Zampolli. “n-3 fatty acids: antiatherosclerotic effects.” Lipids 36:S69–S78 (2001).
• Dehmer, G. J., J. J. Popma, E. K. van den Ber, E. J. Eichorn, J. B. Prewitt, W. B. Campbell, L. Jennings, J. T. Willerson, and J. M. Schmitz. “Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids.” N Engl J Med 319:733–740 (1988).
• DeLongeril, M., S. Renaud, N. Mamelle, P. Salen, J. L. Martin, I. Monjaud, J. Guidollet, P. Touboul, and J. Delaye. “Mediterranean alpha-linolenic acid rich diet in secondary prevention of coronary heart disease.” Lancet 343:1454–1459 (1994).
• DeLongeril, M., P. Salen, and J. Delaye. “Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease.” J Am Coll Cardiology 28:1103–1108 (1996).
• DeLongeril, M., P. Salen, J. L. Martin, I. Monjaud, J. Delaye, and N. Mamelle. “Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.” Circulation 99:779–785 (1999).
• Depres, J-P., B. Lamarche, P. Mauriege, B. Cantin, G. R. Dagenais, S. Moorjani, and P-J. Lupien. “Hyperinsulinemia as an independent risk factor for ischemic heart disease.” N Engl J Med 334:952–957 (1996).
• Depres, J-P., B. Lamarche, P. Mauriege, B. Cantin, P. J. Lupien, and G. R. Dagenais. “Risk factors for ischaemic heart disease: is it time to measure insulin?” Eur Heart J 17:1453–1454 (1996).
• Diomede, L., D. Albani, M. Sottocorno, M. B. Donati, M. Bianchi, Fruscella, and M. Salmona. “In vivo anti-inflammatory effect statins is mediated by nonsterol mevalonate products.” Arterioscler Thromb Vasc Biol 21:1327–1332 (2001).
• Draznin, B., P. Miles, Y. Kruszynska, J. Olefsky, J. Friedman, I. Golovchenko, R. Stjernholm, K. Wall, M. Reitman, D. Accili, R. Cooksey, D. McClain, and M. Goalstone. “Effects of insulin on the prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia.” Endocrinology 141:1310–1316 (2000).
• Dreon, D. M., H. A. Fernstrom, B. Miller, and R. M. Krauss. “Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men.” FASEB J 8:121–126 (1994).
• Dreon, D. M., H. A. Fernstrom, P. T. Williams, and R. M. Krauss. “A very-low fat is not associated with improved lipoprotein profiles in men with a predominance of large, low-density lipoproteins.” Am J Clin Nutr69:411–418 (1999).
• Duimetiere, P., E. Eschwege, G. Papoz, J. L. Richard, J. R. Claude, and G. Rosselin. “Relationship of plasma insulin to the incidence of myocardial infraction and coronary heart disease mortality in a middle-aged population.” Diabetologia 19:205–210 (1980).
• Durrington, P. N. “Triglycerides are more important in atherosclerosis than epidemiology has suggested.” Atherosclerosis 141:S57–S62 (1998).
• Dyerberg, J., H. O. Bang, E. Stofferson, S. Moncada, and J. R. Vane. “Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis.” Lancet ii:117–119 (1978).
• Eritsland, J., H. Arnesen, K. Bronseth, N. B. Fjeld, and M. Abdelnoor. “Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency.” Am J Cardiol 77:31–36 (1996).
• Erkkila, A. T., S. Lehto, Pyorala, and M. I. J. Uusitupa. “n-3 fatty acids and 5-yrisks of death and cardiovascular disease events in patients with coro-nary artery disease.” Am J Clin Nutr 78:65–71 (2003).
• Eschwege, E., J. L. Richard, N. Thibult, P. Ducimetiere, J. M. Warsnot, J. R.Claude, and G. E. Rosselin.”Coronary heart disease mortality in relationwith diabetes, blood glucose, and plasma insulin levels.” Horm Metab ResSuppl 15:41–46 (1985).
• Ferns, G. A. A. “Differential effects of statins on serum CRP levels.” Athero-sclerosis 169:349–351 (2003).
• Fischer, S., P. C. Weber, and J. Dyerberg. “The prostacyclin/thromboxane balance is favourably shifted in Greenland Eskimos.” Prostaglandins 32:235–241 (1986).
• Fontbonne, A., M. A. Charles, N. Thibult, J. L. Richard, J. R. Claude, J. M. Warnet, G. E. Rosselin, and E. Eschwege. “Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population. The Paris Prospective Study, 15 year follow-up.” Diabetologia 34:356–361 (1991).
• Ford, E. S. and S. Liu. “Glycemic index and serum high-density lipoprotin cholesterol concentration among US adults.” Arch Intern Med 161:572–576 (2001).
• Foster, D. “Insulin resistance-a secret killer?” N Engl J Med 320:733–734 (1989).
• Frolkis, J. P., G. L. Pearce, V. Nambi, S. Minor, and D. L. Sprecher. “Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in private practice.” Am J Med 113:625–629 (2002).
• Gaziano, J. M., C. H. Hennekens, C. J. O’Donnell, J. L. Breslow, and J. E. Buring. “Fasting triglycerides, high-density lipoproteins and risk of myocardial infarction.” Circulation 96:2520–2525 (1997).
• Gaziano, J. M., P. J. Skerrett, and J. E. Buring. “Aspirin in the treatment and prevention of cardiovascular disease.” Haemostasis 30:1–13 (2000).
• Gertler, M., H. E. Leetma, E. Saluste, J. L. Rosenberger, and R. G. Guthrie. “Ischemic heart disease, insulin, carbohydrate and lipid inter-relationship.” Circulation 46:103–111 (1972).
• Gillman, M. W., A. Cupples, B. E. Millen, C. Ellison, and P. A. Wolf. “Inverse association of dietary fat with development of ischemic stroke in men.” JAMA 278:2145–2150 (1997).
• Ginsburg, G. S., C. Safran, and R. C. Pasternak. “Frequency of low serum high density lipoprotein cholesterol levels in hospitalized patients with ‘desireable’ total cholesterol levels.” Am J Cardiol1:187–192 (1991).
• Ginsberg, H. N. “Insulin resistance and cardiovascular disease.” J Clin Invest 106:453–458 (2000).
• GISSI-Prevenzione Investigators. “Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.” Lancet 354:447–455 (1999).
• Glueck, C. J., J. E. Lang, T. Tracy, L. Sieve-Smith, and P. Wang. “Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients.” Metabolism 48:1437–1444 (1999).
• Goto, D., S. Fujii, and A. Kitabatake. “Rho/Rho kinase as a novel theraeutic target in the treatment of cardiovascular diseases.” Drugs of the Future 28:267–271 (2003).
• Gould, K. L. “Very low-fat diets for coronary heart disease: perhaps but which one.” JAMA 275:1402–1403 (1996).
• Grundy, S. M. “Small LDL, atherogenic dyslipidemia, and the metabolic syndrome.” Circulation 95:1–4 (1997).
• Haffner, S. M., L. Mykkanen, M. P. Stern, and R. Valdez, J. A. Heisserman, and R. R. Bowsher. “Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects.” Diabetes 42:1297–1302 (1993).
• Harris, T. B., L. Ferrucci, R. P. Tracy, M. C. Corti, S. Wacholder, W. H. Ettinger, H. Heimovitz, H. J. Cohen, and R. Wallace. “Association of elevated inter-leukin-6 and C-reactive protein levels with mortality in the elderly.” Am JMed 106:506–512 (1999).
• Harris, W. S. “n-3 fatty acids and serum lipoproteins: human studies.” Am JClin Nutr 65:1645S–1654S (1997).
• Harris, W. S., H. N. Ginsberh, N. Arunakul, N. S. Shachter, S. L. Windsor, M. Adams, L. Berlund, and K. Osmundsen. “Safety and efficacy of Omacor in severe hypertriglyceridemia.” J Cardiovasc Risk 4:385–392 (1997).
• Harris, W. S. “n-3 fatty acids and human lipoprotein metabolism: an update.” Lipids34:S257–S258 (1999).
• Harris, W. S., and W. L. Isley. “Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids.” Curr Atheroscler Rep 3:174–179. (2001).
• Hegele, R. A. “Premature atherosclerosis associated with monogenic insulin resistance.” Circulation 103:2225–2229 (2001).
• Hirai, A., T. Hamazaki, T. Terano, T. Nishikawa, Y. Tamura, A. Kumagai, and J. Sajiki. “Eicosapentaenoic acid and platelet function in Japanese.” Lancet ii:1132 (1982).
• Hirai, A., T. Terano, Y. Tamura, and S. Yoshida. “Eicosapentaenoic acid and adult disease in Japan.” J Intern Med 225:69–75 (1989).
• Hollenbeck, C. and G. M. Reaven. “Variations in insulin-stimulated glucoseuptake in healthy individuals with normal glucose tolerance.” J ClinEndocrinol Metab 64:1169–1173 (1987).
• Horne, B. D., J. B. Muhlestein, J. F. Carlquist, T. L. Bair, T. E. Madsen, N. I. Hart, and J. L. Anderson. “Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease.” J Am Coll Cardiol 36:1774–1780 (2000).
• Howard, B. V. “Insulin resistance and lipid metabolism.” Am J Cardiol 84:28J 32J (1999).
• Hrboticky, N., L. Tang, B. Zimmer, I. Lux, and P. C. Weber. “Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines.” JClin Invest93:195–203 (1994).
• Hu, F. B., E. Cho, K. M. Rexrode, C. M. Albert, and J. E. Manson. “Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women.” Circulation 107:1852–1857 (2003).
• Hu, F. B., J. E. Manson, and W. C. Willett. “Types of dietary fat and risk of coronary heart disease: a critical review.” JAm Coll Nutr20:5–19 (2001).
• Hu, F. B., M. J. Stampfer, J. E. Manson, E. Rimm, G. A. Colditz, F. E. Speizer, C. H. Hennekens, and W. C. Willett. “Dietary protein and risk of ischemic heart disease in women.” Am J Clin Nutr 70:221–227 (1999).
• Hudgins, L. C., M. Hellerstein, C. Seidman, and J. Hirsch. “Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet.” J Clin Invest97:2081–2091 (1996).
• Ikeda, U., M. Takahashi, and K. Shimad. “C-reactive protein directly inhibits nitric oxide production by cytokine-stimulate vascular smooth muscle cells.” Cardiovasc Pharmacol 42:607–611 (2003).
• Iso, H., S. Sato, A. R. Falsm, T. Shimamoto, A. Terao, R. G. Munger, A. Kitamure, M. Konishi, M. Iida, and Y. Komachi. “Serum fatty acids and fish intake in rual Japanese, urban Japanese, Japanese American and Caucasian American men.” Int J Epidemiol 18:374–381 (1989).
• Jeppesen, J., H. O. Hein, P. Suadicani, and F. Gyntelberg. “Relation of high TGlow HDL cholesterol and LDL cholesterol to the incidence of ischemicheart disease-an 8-year follow-up in the Copenhagen Male Study.” Arte-rioscler Thromb Vasc Biol 17:1114–1120 (1997).
• Jeppesen, J., H. O. Hein, P. Suadicani, and F. Gyntelberg. “Low triglycerides high high-density lipoprotein cholesterol and risk of ischemic heart disease.” Arch Intern Med 161:361–366 (2001).
• Job, F. P., J. Wolfertz, R. Meyer, A. Hubinger, F. A. Gries, and H. Kuhn.“Hyperinsulinism in patients with coronary artery disease.” CoronaryArtery Disease 5:487–492 (1994).
• Kagawa, Y., M. Nishizawa, M. Suzuki, T. Miyatake, T. Hamamoto, K. Goto, E. Motonaga, H. Izumikawa, H. Hirata, and A. Ebihara. “Eicosapolyenoic acid of serum lipids of Japanese islanders with low incidence of cardiovascular diseases.” J Nutr Sci Vitaminol 28:441–453 (1982).
• Kang, J. X., and A. Leaf. “The cardiac antiarrhythmic effects of polyunsaturated fatty acids.” Lipids S541–544 (1996). Kannel, W. B., W. P. Castelli, and T. Gordon. “Cholesterol in the prediction of atherosclerotic disease.” Ann Intern Med 90:85–91 (1979).
• Kano, H., T. Hayashi, D. Sumi, T. Esaki, Y. Asai, N. K. Thakur, M. Jayachandran, and A. Iguchi. “A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA.” Biochem Biophys Res Commun 259:414–419 (1999).
• Kaplan, N. “The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.” Arch Intern Med 149:1514–1520 (1989).
• Karhapaa, P., M. Malkki, and M. Laakso. “Isolated low HDL cholesterol: an insulin-resistant state.” Diabetes43:411–417 (1994).
• Katan, M. B., S. M. Grundy, and W. C. Willett. “Beyond low-fat diets.” N Engl JMed 337:563–566 (1997).
• Kereiakes, D. J. “The fire that burns within.” Circulation 107:373–374 (2003).
• Kesaniemi, Y. A. “Relevance of the reduction of triglycerides in the prevention of coronary heart disease.” Curr Opin Lipidol 9:571–574 (1998).
• Kiinjo, K., H. Sato, Y. Ohnishi, E. Hisida, Nakaka, Y. Matsumura, H. Takeda, and M. Hori. “Impact of high-sensitivity C-reactive protein on predicting long term mortality of acute myocardial infarction.” Am J Cardiol 91:9331–935 (2003).
• Kluft, C. and M. P. M. de Maat. “Genetics of C-reactive protein.” ArteriosclerThromb Vasc Biol 23:1956–1959 (2003).
• Knopp, R. H. “Serum lipids after a low-fat diet.” JAMA 279:1345–1346 (1998).
• Knopp, R. H., C. E. Walden, B. M. Retzlaff, B. S. McCann, A. A. Dowdy, J. J. Albers, G. O. Gey, and M. N. Cooper. “Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: the dietary alternative study.” JAMA 278:1509–1515 (1997).
• Koh, K. K. “Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.” Cardio Res 1:23–32 (2000).
• Kondo, T., K. Ogawa, T. Satake, M. Kitazawa, M. Taki, and S. Sugiyama. “Plasma-free eicosapentaenoic/arachidonic acid ratio: a possible new coronary risk factor.” Clinical Cardiology9:413–416 (1986).
• Kris-Etherton, P. M., W. S. Harris, and L. J. Appel. “Omega-3 fatty acids and cardiovascular disease: new recommendations frm the American Heart Association.” Arterioscler Thromb Vasc Biol 23:151–152 (2003).
• Kromann, N., and A. Green. “Epidemiological studies in the Upernavik district,Greenland. Incidence of some chronic diseases 1950–1974.” Acta MedScand 208:401–406 (1980).
• Laino, C. “Trans fatty acids in margarine can increase MI risk.” Circulation 89:94–101 (1994).
• Lakshmanan, M. R., C. M. Nepokroeff, G. C. Ness, R. E. Dugan, and J. W.Porter. “Stimulation by insulin of rat liver beta hydroxy methyl HMGCoAreductase and cholesterol synthesizing activities.” Biochem Biophys ResCommun 50:704–710 (1973).
• Lamarche, B., J-P. Despres, S. Moorjani, B. Cantin, G. R. Dagenais, and P. J.Lupien. “Triglycerides and HDL-cholesterol as risk factors for ischemicheart disease: results from the Quebec Cardiovascular Study.” Athero-sclerosis 119:235–245 (1996).
• Lamarche, B., I. Lemieux, and J-P. Despres. “The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, pathophysiology and therapeutic aspects.” Diabetes Metab 25:199–211 (1999).
• Lamarche, B., L. Rashid, and G. F. Lewis. “HDL metabolism in hypertriglyceridemic states: an overview.” Clin Chim Acta 286:145–161 (1999).
• Lamarche, B., A. Tchernof, G. R. Dagenais, B. Cantin, P. J. Lupien, and J-P.Despres. “Small, dense LDL particles and the risk of ischemic heart dis-ease: prospective results from the Quebec Cardiovascular Study.” Circula-tion 95:69–75 (1997).
• Lamarche, B., A. Tchernot, P. Mauriege, B. Cantin, G. R. Gagenais, P. J. Lupien, and J-P. Despres. “Fasting insulin and apolipoprotein B levels and low-density particle size as risk factors for ischemic heart disease.” JAMA 279:1965–1961 (1998).
• Laws, A., A. C. King, W. L. Haskell, and G. M. Reaven. “Relation of fasting plasma insulin concentration to high density lipoprotein cholesterol and triglyceride concentration in men.” Arterioscler Thromb Vasc Biol 11:1636–1642 (1991).
• Laws, A. J. and G. M. Reaven. “Evidence for an independent relationship between insulin resistance and fasting HDL-cholesterol, triglyceride and insulin concentrations.” J Intern Med 231:25–30 (1992).
• Laws, A. and G. M. Reaven. “Insulin resistance and risk factors for coronary heart disease.” Clin Endocrinol Metab 7:1063–1078 (1993).
• Leaf, A. “Dietary prevention of coronary heart disease: the Lyon diet heart study.” Circulation 99:733–735 (1999).
• Leaf, A. and J. X. Kang. “Dietary n-3 fatty acids in the prevention of lethal cardiac arrhythmias.” Curr Opin Lipidol 8:4–6 (1997).
• Leaf, A., J. X. Kang, Y-F. Xiao, and G. E. Billman. “n-3 fatty acids in the prevention of cardiac arrhythmias.” Lipids 34:S187-S189 (1999).
• Leaf, A. J. X. Kang, Y-F. Xiao, and G. E. Billman. “Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils.” Circulation 107:2646–2652 (2003).
• Leaf, A. and P. C. Weber. “Cardiovascular effects of omega-3 fatty acids.” N Engl J Med 318:549–557 (1988).
• Lefer, A. M., R. Scalia, and D. J. Lefer. “Vascular effect of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.” Cardiovascular Res 49:281–287 (2001).
• Lefer, D. J. “Statins as potent anti-inflammatory drugs.” Circulation 106:2041–2042 (2002).
• Libby, P. “Inflammation in atherosclerosis.” Nature 20:868–874 (2002).
• Lichtenstein, A. H. “Trans fatty acids and cardiovascular disease risk.” CurrOpin Lipidol 11:37–42 (2000).
• Lichtenstein, A. H. and L. van Horn. “Very low fat diets.” Circulation 98:935–939 (1998).
• Liu, S., W. C. Willett, M. J. Stampfer, F. B. Hu, M. Franz, L. Sampson, C. H. Hennekens, and J. E. Manson. “A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women.” Am J Clin Nutr 71:1455–1461 (2000).
• Lopez, P. M. and R. M. Ortega. “Omega-3 fatty acids in the prevention and control of cardiovascular disease.” Eur J Clin Nutr57:S22-S25 (2003).
• Lundman, P., M. J. Eriksson, A. Silveia, L-O. Hansson, J. Pernow, C-G. Ericsson, A. Hamsten, and P. Tornvall. “Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation.” Am J Cardiol 91:1128–1131 (2003).
• Madsen, T., J. H. Christensen, M. Blom, and E. B. Schmidt. “The effect ofdietary N-3 fatty acids on serum concentrations of C-reactive protein.” BrJ Nutr 89:517–522 (2003).
• Marcheselli, V. L., S. Hong, W. J. Lukiw, X. H. Tian, K. Gronert, A. Musto, M. Hardy, J. M. Gimenz, N. Chian, C. N. Serhan, and G. Bazan. “Novel docosanoids inhibit brain ischemia-reperfusion-mediate leukocyte infiltration and pro-inflammatory gene expression.” J Biol Chem 278:43807–43817 (2003).
• Marchioli, R., F. Barzi, E. Bomba, and C. Chieffo. “Early protection against sud-den death by n-3 polyunsaturated fatty acid after myocardial infarction.” Cir-culation 105:1897–1903 (2002).
• Marz, W., K. Winkler, M. Nauck, B. Bohm, and B. R. Winkelmann. “Effect of statins on C-reactive protein and interleukin-6.” Am J Cardiol92:305–308 (2003).
• McLaughlin, T., F. Abbasi, C. Lamendola, H. Yen-Komshian, and G. Reaven.“Carbohydrate-induced hypertriglyceridemia: an insight into the linkbetween plasma insulin and triglyceride concentrations.” J Clin EndocrinolMetab 85:3085–3088 (2000).
• McNamara, J. R., J. L. Jenner, Z. Li, P. W. Wilson, and E. J. Schaefer. “Change in LDL particle size is associated with change in plasma triglyceride concentration.” Arterioscler Thromb Vasc Biol 12:1284–1290 (1992).
• Meagher, E. A., O. P. Barry, J. A. Lawson, J. Rokach, and G. A. FitzGerald. “Effects of vitamin E on lipid peroxidation in healthy persons.” JAMA 285:1178–1182 (2001).
• Modan, M., J. Or, A. Karasik, Y. Drory, Z. Fuchs, A. Lusky, and A. Cherit. “Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease.” Circulation 84:1165–1175 (1991).
• Moghadasian, M. H. “Experimental atherosclerosis. A historical overview.” Life Sci70:855–865 (2002).
• Nair, S. S. D., J. W. Leitch, J. Faalconer, and M. Garg. “Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action.” J Nutr 127:383–393 (1997).
• Nakamura, T., A. Azuma, T. Kuribayashi, H. Sugihara, S. Okuda, and M. Nakagawa. “Serum fatty acid levels, dietary style and coronary heart in three neighboring areas in Japan.” Brit J Nutr89:267–272 (2003).
• O’Keefe, J. H., and W. S. Harris. “Omega-3 fatty acids: time for clinical implementation?” Am J Cardiol 85:1239–1241 (2000).
• Okumuar, T., Y. Fujioka, S. Morimoto, S. Tsuboi, M. Masai, T. Tsujino, M. Ohyanagi, and T. Iwasaki. “Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability.” Am J Med Sci 324:247–253 (2002).
• Okuyama, H. “High n-6 to n-3 ratio of dietary fatty acid rather than serumcholesterol as a major risk factor for coronary heart disease.” Eur J LipidSci and Tech 103:418–422 (2001).
• Olser, W. Lectures on Angina Pectoris and Allied States.New York: Appleton, 1897.
• Olszewski, A. J. “Fish oil decreases homocysteine in hyperlipidemic men.” Coronary Artery Dis 4:53–60 (1993).
• Orchard, T. J., D. J. Becker, M. Bates, L. H. Kuller, and A. L. Drash. “Plasmainsulin and lipoprotein concentrations: an atherogenic association?” Am JEpidem 118:326–337 (1983).
• Ornish, D., L. W. Scherwitz, J. H. Billings, K. L. Gould, T. A. Merritt, S. Sparler, W. T. Armstrong, T. A. Ports, R. L. Kirkeeide, C. Hogeboom, and R. J. Brand. “Intensive lifestyle changes for reversal of coronary heart disease.” JAMA 280:2001–2007 (1998).
• Palinski, W. “New evidence for beneficial effects of statins unrelated to lipid lowering.” Arterioscler Thromb Vasc Biol 21:3–5 (2001).
• Papanicolau, D. A. and A. N. Vgontzas. “Interleukin-6: the endocrine cytokine.” J Clin Endocrinol Metab 85:1331–1332 (2000).
• Pentikainen, M. O., K. Oorni, M. Ala-Korpela, and P. T. Kovaen. “Modified LDL-trigger of atherosclerosis and inflammation in the arterial initima.” JInternMed 247:359–370 (2000).
• Perry, I. J., S. G. Wannamethee, P. H. Whincup, A. G. Shaper, M. K. Walker, and K. G. Alberti. “Serum insulin and incident coronary heart disease in middle-aged British men.” Am J Epidemiol 144:224–234 (1996).
• Pinkey, J. A., C.D. Stenhower, S. W. Coppack, and J. S. Yudkin.”Endothelial cell dysfunction: cause of insulin resistance syndrome.” Diabetes 46:S9–S13 (1997).
• Pirro, M., J. Bergeron, G. R. Dagenais, P-M. Bernard, B. Cantin, J-P. Depres, and B. Lamarche. “Age and duration of follow-up as modulators of the risk for ischemic heart disase associated with high plasma C-reactive protein levels in men.” Arch Intern Med 161:2474–2480 (2001).
• Pyorala, K., E. Savolainen, S. Kaukula, and J. Haapakowski. “Plasma insulin as coronary heart disease risk factor.” Acad Med Scand 701:38–52 (1985).
• Pyorala, M., H. Miettinen, P. Halonen, M. Laasko, and K. Pyorala. “Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men.” Arterioscler Thromb Vasc Biol 20:538–544 (2000).
• Rader, D. J. “Inflammatory markers of coronary risk.” N Engl J Med 343:11790–1182 (2000).
• Ravnskov, U. The Cholesterol Myths. Washington DC: New Trends Publishing, 2000.
• Reaven, G. M. “Role of insulin resistance in human disease.” Diabetes 37:1595–1607 (1989).
• Reaven, G. M. “The role of insulin resistance and hyperinsulinemia in coronary heart disease.” Metabolism 41:16–19 (1992).
• Reaven, G. M., Y. D. Chen, J. Jeppesen, P. Maheux, and R. M. Krauss. “Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.” JClin Invest92:141–146 (1993).
• Ridker, P. M. “High-sensitivity C-reactive protein.” Circulation 103:1813–1818 (2001).
• Ridker, P. M., M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens. “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.” N Engl J Med 336:973–979 (1996).
• Ridker, P. M., R. J. Glynn, and C. H. Hennekens. “C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.” Circulation97:2007–2011 (1997).
• Ridker, P. M., C. H. Hennekens, J. E. Buring, and N. Rifai. “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.” New Engl J Med 42:836–843 (2000).
• Rise, P., S. Ghezzi, and C. Galli. “Relative potencies of statins in reducing cholesterol synthesis and enhancing linoleic acid metabolism.” Eur J Pharmcol 467:73–75 (2003).
• Rise, P., F. Pazzucconi, C. R. Sirtori, and C. Galli. “Statins enhance arachidonic acid synthesis in hypercholesterolemic patients.” Nutr Metab Cardiovasc Dis 11:88–94 (2001).
• Rodwell, V. W., J. L. Nordstrom, and Mitschelen. “Regulation of HMG-CoA reductase.” Adv Lipid Res 14:1–76 (1976).
• Rohde, L. E. P., C. H. Hennekens, and P. M. Ridker. “Survey of C-reactive pro-tein and cardiovascular risk factors in apparently healthy men.” Am J Car-diol 84:1018–1022 (1999).
• Rosamond, W. D., L. E. Chambless, A. R. Folsom, L. S. Cooper, D. E. Conwill, L. Legg, Ch-H. Wang, and G. Heiss. “Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.” N Engl J Med 339:861–867 (1998).
• Ross, R. “The pathogensis of atherosclerosis: a perspective for the 1990s.” Nature 362:801–809 (1993).
• Ross, R. “Atherosclerosis is an inflammatory disease.” N Engl J Med 340:115–126 (1999).
• Rubins, H. B., S. J. Robins, D. Collins, A. Iranmanesh, T. J. Wilt, D. Mann, M. Mayo-Smith, F. H. Fass, M. R. Elam, and G. H. Rutan. “Distribution of lipids in 8,500 men with coronary heart disease.” Am J Cardiol 75:1196–1201 (1995).
• Sacks, F. M., M. A. Pfeffer, L. A. Moye, J. L. Pouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. Arnold, C. C. Wun, B. R. Davis, and E. Braunwald. “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.” N Engl J Med 335:1001–1009 (1996).
• Salmeron, J., J. E. Manson, M. J. Stampfer, G. A. Colditz, A. L. Wing, and W. C. Willett. “Dietary fiber, glycemic load, and risk of coronary heart disease in women.” JAMA 277:472–477 (1997).
• Scandinavian Simvastatin Survival Study Group. “Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S).” Lancet 344:1383–1389 (1994).
• Sears, B. The Zone.New York: ReganBooks, (1995).
• Sears, B. TheAnti-Aging Zone.New York: ReganBooks, (1999).
• Sears, B. The Omega Rx Zone.New York: ReganBooks, (2002).
• Serhan, C. N. and E. Oliw. “Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways.” J Clin Invest 107:1481–1489 (2001).
• Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert. “Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.” J Exp Med 192:1197–1204 (2000).
• Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, K. Gronert, and N. Chiang. “Anti-microinflammatory lipid signals generated from dietary n-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and n-3 PUFA therapeutic actions.” J Physiol Pharmacol 51:643–654 (2000).
• Serhan, C. N., K. Gotlinger, S. Hong, and M. Arita. “Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin triggered endogenous epimers: an overview of their protective roles in catabasis.” Prostaglandins Other Lipid Mediat 73:155–172 (2004).
• Serhan, C. N. “Lipoxins and novel aspirin-triggered 15-epi-lipoxins.”Prostaglandins 53:107–137 (1997).
• Shanoff, H. M., J. A. Little, and A. Csima. “Studies of male survivors of myocardial infarction: xii. Relation of serum lipids and lipoproteins to survival over a 10-year period.” Can Med Assoc J 103:927–931 (1970).
• Sinclair, H. M. “Deficiency of essential fatty acids and atherosclerosis, et cetera.” Lancet i:381–383 (1956).
• Singh, R. B., M. A. Niaz, J. P. Sharma, R. Kumar, V. Rastogi, and M. Moshiri. “Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction. The Indian Experiment of Infarct Survival-4.” Cardiovasc Drugs Ther 11:485–491 (1997).
• Siscovick, D. S., R. N. Lemaitre, and D. Mozaffarian. “The fish story. A diet heart hypothesis with clinical implications: n-3 polyunsaturated fatty acids, myocardial vulnerability, and sudden death.” Circulation 107:2632–2634 (2003).
• Solheim, S., H. Arnesen, L. Eikvar, M. Hurlen, and I. Seljeflot. “Influence of aspirin on inflammatory markers in patients after acute myocardial infarction.” Am J Cardiol 92:843–845 (2003).
• Sprecher, D. L. “Triglycerides as a risk factor for coronary artery disease.” Am J Cardiol 82:49U–56U (1998).
• Steering Committee of Physicians Health Study Research Group. “Preliminary Report: findings for aspirin component of the on-going physician health study.” N Engl J Med 320:262–264 (1988).
• Stout, R. “The relationship of abnormal circulating insulin levels to atherosclerosis.” Atherosclerosis 27:1–13 (1977).
• Tchernof, A., B. Lamarche, D. Prud’Homme, A. Nadeau, S. Moorjani, F. Labrie, P. J. Lupien, and J. D. Depres. “The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men.” Diabetes Care 19:629–637 (1996).
• Thies, F., J. M. C. Garry, P. Yaqoob, K. Kerkasem, J. Williams, C. P. Shearman, P. J. Gallaher, P. C. Calder, and R. F. Grimble. “Association of n-3 polyunsaturated fatty with stability of atherosclerotic plaques.” Lancet 361:477–485 (2003).
• Thompson, P. D. “More on low-fat diets.” New Engl J Med 338:1623–1624 (1998).
• Torjesen, P. A., K. J. Kirkeland, S. A. Andersson, I. Hjermann, I. Holme, and P. Urdal. “Lifestyle chanages may reverse development of the insulin resistance syndrome.” Diabetes Care 30:26–31 (1997).
• Tracy, R. P. “Inflammation in cardiovascular disease.” Arterioscler Thromb VascBiol 22:1514–1515 (2002).
• Van der Meer, I. R., P. M. de Maat, A. J. Kiliaan, D. A. M. van der Kuip, A. Hofman, and J. A. M. Witteman. “The value of C-reactive protein in cardiovascular risk prediction.” Arch Intern Med 163:13231328 (2003).
• Villa, B., L. Calabresi, G. Chiesa, P. Rise, C. Galli, and C. R. Sirtori. “Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease.” Pharmacol Res 45:475 (2002).
• Virchow, R. Die cellularpathologie in ihrer begrundung auf physiologische undpathologische gewebelehre. Berlin: Verlag von August Hirschwald, 1858.
• Volek, J. S., A. L. Gomez, and W. J. Kraemer. “Fasting lipoprotein and postprandial triacylglycerol responses to a low-carbohydrate diet supplemented with n-3 fatty acids.” J Am Coll Nutr 19:383–391 (2000).
• Von Lente, F. V. “Markers of inflammation as predictors in cardiovascular disease.” Clin Chim Acta 293:31–52 (2000).
• Von Schacky, C. “Omega-3 fatty acids: from Eskimos to clinical cardiology— what took us so long?” World Rev Nutr Diet 88:90–99 (2001).
• Von Schacky, C. “Prophylaxis of atherosclerosis with marine omega-3 fatty acids.” Ann Intern Med 107:890–899 (1987).
• Von Schacky, C., P. Angerer, W. Kothny, K. Theisen, and H. Mudra. “The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind placebo-controlled trial.” Ann Intern Med 130:554–562 (1999).
• Weiner, B. H., I. S. Ockene, P. H. Levine, H. F. Cuenoud, M. Fisher, B. F. John-son, A. S. Daoud, J. Jarmolych, D. Hosmer, and M. H. Johnson. “Inhibitionof atherosclerosis by cod-liver oil in a hyperlipidemic swine model.” N EnglJ Med 315:841–846 (1986).
• Westphal, S. A., M. C. Gannon, and F. Q. Nutrall. “Metabolic response to glucose ingested with various amounts of protein.” Am J Clin Nutr 62:267–272 (1990).
• Wierzbicki, A. S., R. Poston, and A. Ferro. “The lipid and non-lipid effects of statins.” Pharmacol and Therapeutics 99:95–112 (2003).
• Willams, P. T. and R. M. Krauss. “Low-fat diets, lipoprotein subclasses, and heart disease risk.” Am J Clin Nutr70:949–950 (1999).
• Yarnell, J. W. G., P. M. Sweetnam, V. Marks, and J. D. Teale. “Insulin in ischaemic heart disease: are associations explained by triglyceride concentrations? The Caerphilly prospective study.” Br Heart J 171:293–296 (1994).
• Young, B., M. Gleeson, and A. W. Cripps. “C-reactive protein: a critical review.” Pathology 23:118–124 (1991).
• Yudkin, J. S., M. Kumari, S. E. Humphries, and V. Mohamed-Ali. “Inflammation,obesity, stress and coronary heart disease: is interleukin-6 the link?” Ath-erosclerosis 148:209–214 (2000).
• Zaman, A. G., G. Helft, S. G. Worthley, and J. J. Badimon. “The role of plaquerupture and thombosis in coronary artery disease.” Artheosclerosis (Ire-land) 149:251–266 (2000).
• Zavroni, I., L. Bonini, M. Fantuzzi, E. Dall’Aglio, M. Passeri, and G. M. Reaven. “Hyperinsulinemia, obesity, and syndrome X.” J Intern Med 235:51–56 (1994).
• Zavaroni, I., E. Bonora, M. Pagliara, E. Dall’Aglio, L. Luchetti, G. Buonnanno, P.A. Bonati, M. Bergonzani, L. Gnudi, M. Passeri, and G. Reaven. “Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance.” N Engl J Med 320:702–706 (1989).
• Zhou, Y. R., G. Csako, J. T. Grayston, S.P. Wang, Z. X. Yu, M. Shou, M. Leon, and S. E. Epstein. “Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae.” Am J Cardiol84:595–598 (1999).
• Zwaka, T. P., V. Hombach, and Torzewski. “C-reactive protein-mediated low density lipoprotein uptake by macrophage: implications for atherosclerosis.” Circulation 103:2094–2099 (2000).

• Ablin, R. J. and M. W. Shaw. “Prostaglandin modulation of prostate tumor growth and metastases.” Anticancer Res 6:327–388 (1986).
• Akre, K., A. M. Ekstrom, L. B. Signorello, L. E. Hansson, and O. Nyren. “Aspirin and risk for gastric cancer.” Br J Cancer 84:965–968 (2001).
• Aktas, H. and J. A. Halperin. “Translational regulation of gene expression by omega-3 fatty acids.” J Nutr 134:2487S-2491S (2004).
• Aronson, W. J., J. A. Glaspy, S. T. Reddy, D. Reese, D. Heber, and D. Bagga. “Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer.” Urology 58:283–288 (2001).
• Attiga, F. A., P. M. Fernandez, A. T. Weeraratna, M. J. Manyak, and S. R. Patierno. “Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.” Cancer Res 60:4629–4637 (2000).
• Augustin, L. S. A., L. Dal Maso, C. La Vecchia, M. Papinel, E. Negri, S. Vaccarella, C. W. C. Kendal, D. J. A. Jenkins, and S. Francechi. “Dietary glycemic index and glycemic load, and breast cancer risk.” Ann Ocol 12:1533–1538 (2001). Augustsson, K., D. S. Michaud, E. B. Rimm, M. F. Leitzmann, M. J. Stampfer, W. C. Willett, and E. Giovannucci. “A prospective study of intake of fishand marine fatty acids and prostate cancer.” Cancer Epidemiology, Bio-markers and Prevention 12:64–67 (2003).
• Bagga, D., S. Capone, H. J. Wang, D. Heber, M. Lill, L. Chap, and J. A. Glaspy. “Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer.” J Natl Cancer Inst 6:1123–1131 (1997).
• Barber, M. D. “Cancer cachexia and its treatment with fish oil enriched nutritional supplementation.” Nutrition 217:751–755 (2001).
• Barber M. D. and K. C. H. Fearon. “Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia.” Lipids 36:347–351 (2001).
• Barber, M. D., J. A. Ross, and K. C. H. Fearon. “Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer.” Nutr Cancer 35:106–110 (1999).
• Baron, J. A., and R. S. Sandler. “Nonsteroidal anti-inflammatory drugs and cancer prevention.” Ann Rev Med 51:511–523 (2000).
• Baronzio, G. F., F. Galante, A. Gramaglia, A. Barlocco, S. de Grandi, and I. Freitas. “Tumor microcirculation and its significance in therapy: possible role of omega-3 fatty acids as rheological modifiers.” Med Hypotheses 50:175–82 (1998).
• Bartsch, H., J. Nair, and R. W. Owen. “Dietary polyunsaturated fatty acids and cancer of the breast and colorectum: emerging evidence for their role as risk modifiers.” Carcinogenesis20:2209–2218 (1999).
• Bougnoux, P. “n-3 polyunsaturated fatty acids and cancer.” Curr Opin ClinNutr Metab Care 2:121–126. (1999).
• Bougnoux, P., E. Germain, V. Chajes, B. Hubert, C. Lhuillery, O. Le Floch, G.Body, and G. Calais. “Cytotoxic drugs efficacy correlates with adipose tis-sue docosahexaenoic acid level in locally advanced breast carcinoma.” BrJ Cancer 79:1765–1769 (1999).
• Bruce, W. R., Wolever T. M. S, and A. Giacca. “Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance.” Nutr Cancer 37:19–26 (2000).
• Bruning, P. F., J. M. G. Bonfrer, P. A. H. van Noodr, A. A. M. Hart, M. de Jong-Bakker, and W. J. Nooijen. “Insulin resistance and breast cancer.” Int JCancer 52:511–516 (1992).
• Burns, C. P., S. Halabi, G. H. Clamon, V. Hars, B. A. Wagner, R. J. Hohl, E. Lester, J. J. Kirshner, V. Vinciguerra, and E. Paskett. “Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.” Clin Cancer Res 5:3942–3947 (1999).
• Cannizzo Jr., F. and S. A. Broitman. “Postpromotional effects of dietary marine or safflower oils on large bowel or pulmonary implants of CT-26 in mice.” Cancer Res 49:4289–4294 (1989).
• Capuron, L., A. Ravaud, and R. Dantzer. “Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.” J Clin Oncol 18:2143–2151 (2000).
• Chapkin, R. S., N. E. Hubbard, D. K. Buckman, and K. L. Erickson. “Linoleic acid metabolism in metastatic and nonmetastatic murine mammary tumor cells.” Cancer Res 49: 4724–4728 (1989).
• Chatenoud, L., C. La Vecchia, S. Franceschi, A. Tavani, D. R. Jacobs, M. T. Parpinel, M. Sosler, and E. Negri. “Refined-cereal intake and risk of selected cancers in Italy.” Am J Clin Nutr 70:1107–1110 (1999).
• Chen, Y. Q., Z. M. Duniec, B. Liu, W. Hagmann, X. Gao, K. Shimoji, L. J. Marnett, C. R. Johnson, and K. V. Honn. “Endogenous 12(S)-HETE production by tumor cells and its role in metastasis.” Cancer Res 15:1574–1579 (1994).
• Chen, Y. Q., B. Liu, D. G. Tang, and K. V. Honn. “Fatty acid modulation of tumor cell-platelet-vessel wall interaction.” Cancer Metastasis Rev 11:389–409 (1992).
• Cho, E., D. Spiegelman, D. J. Hunter, W. Y. Chen, G. A. Colditz, and W. C. Wil-lett. “Premenopausal dietary carbohydrate, glycemic index, and glycemicload, and fiber in relation to risk of breast cancer.” Cancer Epidemiology,Biomarkers and Prevention 12:1153–1158 (2003).
• Claria, J., M. H. Lee, and C. N. Serhan. “Aspirin-triggered lipoxins are generated by human lung adrenocarcinoma cell (A549)-neutrophil interactions and are potent inhibitors of cell proliferation.” Mol Med 2:583–596 (1996).
• Colas, S., L. Paon, F. Denis, M. Prat, P. Louisot, C. Hoinard, O. Le Floch, G. Ogilive, and P. Bougnoux. “Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid.” Int J Cancer 109:449–454 (2004).
• Connolly, J. M., X. H. Liu, and D. P. Rose. “Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor.” Nutr Cancer 25:231–240 (1996).
• Copeland, G. P., S. J. Leinster, J. C. Davis, and L. J. Hipkin. “Insulin resistance in patients with colorectal cancer.” Br J Surg 74:1031–1036 (1987).
• Damtew, B. and P. J. Spagnuolo. “Tumor cell-endothelial cell interactions: evidence for roles for lipoxygenase products of arachidonic acid in metastasis.” Prostaglandins Leukot Essent Fatty Acids 56:295–300 (1997).
• DeLongeril, M., P. Salen, J. L. Martin, I. Monjaud, P. Boucher, and N. Mamelle. “Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced rate of cancer.” Arch Intern Med 158:1181–1188 (1998).
• Dewailly, E., G. Mulvad, H. S. Pedersen, J. C. Hansen, N. Behrendt, and J. P. H.Hansen. “Inuit are protected against prostate cancer.” Cancer Epidemiol-ogy, Biomarkers and Prevention 12:926–927 (2001).
• DuBois, R. N. F. M. Giardiello, and W. E. Smalley. “Nonsteroidal anti-inflammatorydrugs, eicosanoids, and colorectal cancer prevention.” Gastroenterol ClinNorth Am25:773–791 (1996).
• Dunlop. R. J. and C. W. Campbell. “Cytokines and cancer.” JPain Symptom Man-age 20:214–232 (2000).
• Folsom, A. R., Z. Demissi, and L. Harnack. “Glycemic index, glycemic load, and incidence of endometrial cancer.” Nutr Cancer 46:119–124 (2003).
• Form, D. M. and Auerbach. “PGE2 and angiogenesis.” Exp Biol Med 172:214–218 (1983).
• Ellis, L. M., E. N. Copeland, K. I. Bland, and H. S. Sitren. “Inhibition of tumor growth and metastasis by chronic intravenous infusion of prostaglandin E1.” Ann Surg 212:45–50 (1990).
• Fernandez, E., L. Chatenoud, C. La Vecchia, E. Negri, and S. Franceschi. “Fish consumption and cancer risk.” Am J Clin Nutr 70:85–90 (1999).
• Franceschi, S., L. Dal Maso, L. Augustin, E. Negri, M. Parpinci, P. Boyle, D. J. Jenkins, and C. La Vecchia. “Dietary glycemic load and colorectal cancer risk.” Ann Oncol 12:173–178 (2001).
• Franceschi, S., A. Favero, A. Decari, E. Negri, C. La Vecchia, M. Ferraroni, A. Russo, S. Salvini, D. Amadori, and E. Conti. “Intake of macronutrients and the risk of breast cancer.” Lancet 347:1351–1356 (1996).
• Franceschi, S., A. Favero, M. Parpinel, A. Giacosa, and C. La Vecchia. “Italian study study of colorectal cancer with emphasis on influence of cereals.” Eur J Cancer Prev 7:S19-S223 (1998).
• Franceschi, S., C. La Vecchia, A. Russo, A. Favero, E. Negri, E. Conti, M. Montella, R. Filiberti, D. Amadori, and A. Decarli. “Macronutrient intake and risk of colorectal cancer in Italy.” Int J Cancer76:321–324 (1998).
• Fulton, A. M. “The role of eicosanoids in tumor metastasis.” ProstaglandinsLeukot Essent Fatty Acids 34:229–237 (1988).
• Gago-Dominguez, M., J. E. Castelao, C-L. Sun, D. van den Berg, W-P. Koh, H P. Lee, and M. C. Yu. “Marine n-3 fatty acid intake, glutathione S-transferease polymorphisms and breast cancer risk in postmenopausal Chinese women in Singapore.” Carcinogenesis 25:978–982 (2004).
• Gao, X., W. Hagmann, A. Zacharek, N. Wu, M. Lee, A. T. Porter, and K. V. Honn.“Eicosanoids, cancer metastasis, and gene regulation: an overview.” Adv ExpMed Biol 400A:545–55 (1997).
• Garcia-Rodriguez, L. A., and C. Huerta-Alvarez. “Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsterodial anti inflammatory drugs.” Epidemiology 12:88–93 (2001).
• Germain, E., V. Chajes, S. Cognault, C. Lhuillery, and P. Bougnoux. “Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation.” Int J Cancer 75:578–583 (1998).
• Germain, E., F. Lavandier, V. Chajes, V. Schubnel, P. Bonnet, C. Lhuillery, and P. Bougnoux. “Dietary n-3 polyunsaturated fatty acids and oxidants increase rat mammary tumor sensitivity to epirubicin without change in cardiac toxicity.” Lipids 34:S203 (1999).
• Ghost, J. and C. E. Myers. “Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipooxygenase.” Biochem Biophys Res Commun 235:418–423 (1997).
• Ghost, J. and C. E. Myers. “Arachidonic acid metabolism and cancer of the prostate.” Nutrition 14:48–57 (1998).
• Giardiello, F. M., G. J. Offerhaus, and R. N. DuBois. “The role of nonsteroidal anti inflammatory drugs in colorectal cancer prevention.” Eur J Cancer 31A:1071–1076 (1995).
• Giovannucci, E. “Insulin and colon cancer.” Cancer Causes and Control 6:164–179 (1995).
• Gogos, C. A., P. Ginopoulos, B. Salsa, E. Apostolidou, N. C. Zoumbos, and F.Kalfarentzos. “Dietary omega-3 polyunsaturated fatty acids plus vitaminE restore immunodeficiency and prolong survival for severely ill patientswith generalized malignancy: a randomized control trial.” Cancer 199882:395–402 (1998).
• Hansen-Petrik, M. B., M. F. McEntee, C-H. Chiu, and J. Whelan. “Antagonism of arachidonic acid is linked to the antitumorigenic effect of dietary eicosapentaenoic acid acid in APC mice.” J Nutr 130:1153–1158 (2000).
• Hardman, W. E., C. P. Avula, G. Fernandes, and I. L. Cameron. “Three percent dietary fish oil concentrate increased efficacy of doxorubicin against mda mb 231 breast cancer xenografts.” Clin Cancer Res 7:2041–2049 (2001).
• Hardman, W. E., M. P. Moyer, and I. L. Cameron. “Dietary fish oil sensitizes A549 lung xenografts to doxorubicin chemotherapy.” Cancer Lett 151:145–151 (2000).
• Honn, K. V., D. G. Tang, X. Gao, I. A. Butovich, B. Liu, J. Timar, and W. Hagmann. “12-lipoxygenases and 12(S)-HETE: role in cancer metastasis.” Cancer Metastasis Rev 13:365–396 (1994).
• Honn, K.V., D. G. Tang, I. M. Grossi, C. Renaud, Z. M. Duniec, C. R. Johnson, and C. A. Diglio. “Enhanced endothelial cell retraction mediated by 12(S) HETE: a proposed mechanism for the role of platelets in tumor cell metastasis.” Exp Cell Res 210:1–9 (1994).
• Huang, Y.C., J. M. Jessup, and G. L. Blackburn. “N-3 fatty acids decrease colonic epithelial cell proliferation in high-risk bowel mucosa.” Lipids 31:S313-S316 (1996).
• Hubbar, N. E., D. Lim, and K. L. Erickson. “Alternation of murine mammarytumorigenesis by dietary enrichment with n-3 fatty acids in fish oil.” Can-cer Lett 124:1–7 (1998).
• Hussey, H. J., and M. H. Tidale. “Inhibition of tumour growth by lipoxygenase inhibitors.” Br J Cancer 74:683–687 (1996).
• Hwang, D., D. Scollard, J. Byrne, and E. Levine. “Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.” J Natl Cancer Res 90:455–460 (1998).
• Iniguez, M. A., A. Rodriguez, O. V. Volpert, M. Fresno, and J. M. Redondo.“Cyclooxygenase-2: a therapeutic target in angiogenesis.” Trends in MolMed 9:73–78 (2003).
• Jiag, W. G., R. P. Bryce, and D. F. Horrobin. “Essential fatty acids: molecular andcellular basis of their anti-cancer action and clinical implications.” Crit RevOncol Hematol 27:179–209 (1998).
• Kaizer, L., N. F. Boyd, V. Kriukov, and D. Trichler. “Fish consumption and breast cancer risk.” Nutr Cancer 12:61–68 (1989).
• Karmali, R. “N-3 fatty acids: biochemical actions in cancer.” J Nutr Sci Vita-minol (Tokyo) Spec No:148–52 (1992).
• Karmali, R. A. “Eicosanoids and cancer.” Prog Clin Biol Res 222:687–697 (1986).
• Karmali, R. A. “Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia.” Nutrition 12:S2–S4 (1996).
• Karmali, R. A. “N-3 fatty acids and cancer.” J Intern Med 225:197–200 (1989).
• Kinoshita, K., M. Noguchi, M. Earashi, M. Tanaka, and T. Sasaki. “Inhibitory effects of purified eicosapentaenoic acid and docosahexaenoic acid on growth and metastasis of murine transplantable mammary tumor.” In Vivo 8:371–374 (1994).
• Kopp, E. and S. Ghosh. “Inhibition of NF-kappa B by sodium salicylate and aspirin.” Science 265:956–959 (1994).
• Kort, W. J., I. M. Weijma, A. M. Bijma, W. P. van Schalkwijk, A. J. Vergroesen, and D. L. Westbroek. “Omega-3 fatty acids inhibiting the growth of a transplantable rat mammary adenocarcinoma.” J Natl Cancer Inst 79:593–599 (1987).
• Lane, J., R. E. Mansel, and W. G. Jiang. “Expression of human delta 6-desat-urase is associated with aggressiveness of human breast cancer.” Int JMol Med 12:253:257 (2003).
• Levi, F., C. Pasche, R. Lucchini, L. Chatenoud, D. R. Jacobs, and C. La Vecchia. “Refined and whole grain cereals and the risk of oral, esophageal and laryngeal cancer.” Eur J Clin Nutr54:487–489 (2000).
• Liu, B., R. J. Maher, Y. A. Hannum, A. T. Porter, and K. V. Honn. “12-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha.” J Natl Cancer Inst 86:1145–1151 (1994).
• Lloyd, F. P., V. Slivova, T. Valaachovicova, and D. Sliva. “Aspirin inhibits highly invasive prostate cancer cells.” Int J Oncol 23:1277–1283 (2003).
• Lundholm, K., G. Holm, and T. Schersten. “Insulin resistance in patients with cancer.” Cancer Res 38:4665–4670 (1978).
• Marcus, A. J. “Aspirin as prophylaxis against colorectal cancer.” N Engl J Med 333:656–658 (1995).
• Marks, F., K. Muller-Decker, and A. Furstenberger. “A casual relationshipbetween unscheduled eicosanoid signaling and tumor development: can-cer chemoprevention by inhibitors of arachidonic acid metabolism.” Toxi-cology 153:11–26 (2000).
• McCarty, M. F. “Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production.” Med Hypotheses 46:107–115 (1996).
• McKeown-Eyssen, G. “Epidemiology of colorectal cancer revisted: are serumtriglycerides and/or plasma glucose associated with risk?” Cancer Epi-demiol Biomarkers and Prev 3:687–695 (1994).
• Michaud, D. S., S. Liu, E. Giovannucci, W. C. Willett, G. A. Colditz, and C. S. Fuchs. “Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study.” J Nat Cancer Inst 94:1293–300 (2002).
• Moysich, K. B., C. Mettlin, M. S. Piver, N. Natarajan, R. J. Menezes, and H.Swede. “Regular use of analgesic drugs and ovarian cancer risk.” CancerEpidemiol Biomarkers Prev 10:903–906 (2001).
• Mukutmoni-Norris, M., N. E. Hubbard, and K. L. Erickson. “Modulation of murinemammary tumor vasculature by dietary n-3 fatty acids in fish oil.” CancerLett 150:101–109 (2000).
• Narisawa, T., H. Kusaka, Y. Yamazaki, M. Takahashi, H. Koyama, K. Koyama, Y. Fukaura, and A. Wakizaka. “Relationship between blood plasmaprostaglandin E2 and liver and lung metastases in colorectal cancer.” DisColon Rectum 33:840–845 (1990).
• Natarajan, R. and J. Nadler. “Role of lipoxygenases in breast cancer.” FrontBiosci 3:E81–88. (1998).
• Nie, D., G. G. Hillman, T. Geddes, K. Tang, C. Pierson, D. J. Grignon, and K. V. Honn. “Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth.” Cancer Res 58:4047–4051 (1998).
• Nie, D., J. Nemeth, Y. Qiao, A. Zacharek, L. Li, K. Hanna, K. Tang, G. G. Hillman, M. L. Cher, D. J. Grignon, and K. V. Honn. “Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase.” Clin Exp Metastasis 20:657–663 (2003).
• Nie, D., K. Tang, K. Szekeres, M. Trikha, and K. V. Honn. “The role ofeicosanoids in tumor growth and metastasis.” Ernst Schering Res FoundWorkshop 31:201–217 (2000).
• Nie, D., K. Tang, K. Szekeres, L. Li, and K. V. Honn. “Eicosanoid regulation ofangiogenesis: role of endothelial arachidonate 12-lipoxygenase.” Ann N YAcad Sci 905:165–176 (2000).
• Noguchi, Y., T. Yoskikawa, D. Marat, C. Doi, T. Makin, K. Fukuzawa, A. Tsubu-raya,S.Staoh, T. Ito, and S. Mitsuse. “Insulin resistance in cancer patientsis associated with enhanced tumor necrosis factor expression in skeletalmuscle.” Biochem Biophys Res Commun 253:887–892 (1998).
• Norrish, A. E., C. M. Skeaff, G. L. Arribas, S. J. Sharpe, and R. T. Jackson. “Prostate cancer risk and consumption of fish oils: a dietary biomarker based case-control study.” Br J Cancer 81:1238–1242 (1999).
• Ogilvie, G. K., M. J. Fettman, C. H. Mallinckrodt, J. A. Walton, R. A. Hansen, D. J. Davenport, K. L. Gross, K. L. Richardson, Q. Rogers, and M. S. Hand. “Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study.” Cancer 88:1916–1928 (2000).
• Okuno, K., H. Jinnai, Y. S. Lee, K. Nakamura, T. Hirohata, H. Shigeoka, and M.Yasutomi. “A high level of prostaglandin E2 (PGE2) in the portal vein sup-presses liver-associated immunity and promotes liver metastases.” SurgToday 25:954–958 (1995).
• Pham, H., T. Banerjee, G. M. Nalbandian, and V. A. Ziboh. “Activation of per-oxisome proliferators-activated receptor gamma by 15S-hydroxye-icosatrienoic acid parallels growth suppression of androgen-dependentprostatic adenocarcinoma cells.” Cancer Lett 17–23 (2003).
• Pratt, V. C., S. Watanable, E. Bruera, J. Mackey, M. R. Clandinin, V. E. Baracos, and C. J. Field. “Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation.” Br J Cancer 87:1370–1378 (2002).
• Prescott, S. M. and F. A. Fitzpatrick. “Cyclooxygenase-2 and carcinogenesis.” Biochim Biophys Acta 1470:M69-M78 (2000).
• Radisky, D., C. Hagios, and M. J. Bissell. “Tumors are unique organs defined by abnormal signaling and context.” Cancer Biol 11:87–95 (2001).
• Reich, R. and G. R. Martin. “Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells.” Prostaglandins 51:1–17 (1996).
• Rigas, B., I. S. Goldman, and L. Levine. “Altered eicosanoid levels in human colon cancer.” J Lab Clin Med 122:518–523 (1993).
• Rioux, N. and Castonguay. “Inhibitors of lipoxygenase: a new class of cancerchemopreventative inhibitors.” Carcinogenesis 19:1393–1400 (1998).Rohdeburg, G. L., A. Bernhard, and O. Krehniel. “Sugar tolerance in cancer.” JAMA 72:1528 (1919).
• Rolland, P. H., M. Martin, and M. Toga. “Prostaglandin in human breast cancer: evidence suggesting the elevated prostaglandin production is a marker of high metastatic potential.” J Nat Cancer Inst 64:1061–1070 (1980).
• Rose, D. P. and J. M. Connolly. “Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice.” Int J Oncol 15:1011–1015 (1999).
• Rose, D. P. and J. M. Connelly. “Omega-3 fatty acids as cancer chemopreventive agents.” Pharmacol Ther 83:217–244 (1999).
• Rose, D. P. and J. M. Connolly. “Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids.” Nutr Cancer 37:119–127. (2000).
• Rudra, P. K. and H. E. Krokan. “Cell-specific enhancement of doxorubicin toxicity in human tumour cells by docosahexaenoic acid.” Anticancer Res 21(1A):29–38 (2001).
• Sauer, L. A., R. T. Dauchy, and D. E. Blask. “Mechanism for the antitumor and anticachectic effects of n-3 fatty acids.” Cancer Res 60:5289–5295 (2000).
• Sawaoka, H., S. Tsuji, M. Tsuji, E. S. Gunawan, Y. Sasaki, S. Kawano, and M. Hori. “Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.” Lab Invest 79:79:1469–1477 (1999).
• Schirner, M., R. B. Lichtner, and M. R. Schneider. “The stable prostacyclin analogue Cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3 rat mammary carcinoma.” Clin Exp Metastasis 12:24–30 (1994).
• Schoen, R. E., C. M. Tengen, L. H. Kuller, G. L. Bruke, M. Cushman, R. P. Tracy, A. Dops, and P. J. Savage. “Increased blood glucose and insulin, body size, and incidence of colorectal cancer.” J Natl Cancer Inst 91:1147–1154 (1999).
• Sears, B. The Zone.New York: ReganBooks, 1995.Sears, B. The Anti-Aging Zone.New York: ReganBooks, 1999.Sears, B. The Omega Rx Zone.New York: ReganBooks, 2002.Sheehan, K. M., K. Sherhan, D. P. O’Donoghue, F. MacSweeney, R. M. Conroy, D. J. Fitzgerald, and F. E. Murray. “The relationship between cyclooxygenase-2 expression and colorectal cancer.” JAMA 282:1254–1257 (1999).
• Shiff, S. J. and B. Rigas. “Aspirin for cancer.” Nature Medicine 5:1348–1349 (1999).
• Singh, J., R. Hamid, and B. S. Reddy. “Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the post-initiation stage of colon carcinogenesis.” Cancer Res 57:3465–3470 (1997).
• Steele, V. E., C. A. Holmes, E. T. Hawk, L. Kipelovich, R. A. Lubet, J. A. Crowell, C. C. Sigman, and G. J. Kelloff. “Lipoxygenase inhibitors as potential cancer chemopreventives.” Cancer Epidemiol Biomarkers Prevent 8:467–483 (1999).
• Stoll, B. A. “Essential fatty acids, insulin resistance, and breast cancer risk.” Nutrition and Cancer 31:72–77 (1998).
• Stoll, B. A. “Western nutrition and the insulin resistance syndrome: a link to breast cancer.” Eur J Clin Nutr53:83–87 (1999).
• Takahata, K., M. Tada, K. Yazawa, and T. Tamaki. “Protection from chemotherapy-induced alopecia by docosahexaenoic acid.” Lipids 34:S105 (1999).
• Taketo, M. M. “Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).” JNatlCancer Inst 90:1609–1620 (1998).
• Tang, D. G., C. Renaud, S. Stojakovic, C. A. Diglio, A. Porter, and K. V. Honn. “12-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis.” Biochem Biophys Res Comm 211:462–468 (1995).
• Tang, K., and K. V. Honn. “12(S)-HETE in cancer metastasis.” Adv Exp Med Biol 447:181–191 (1999).
• Terry, P., P. Lichtenstein, M. Feychting, A. Ahlbom, and A. Wolk. “Fatty fish consumption and risk of prostate cancer.” Lancet 357:1764–1766 (2001).
• Thun, M. J. “NSAID use and decreased risk of gastrointestinal cancers.” Gas-troenterol Clin North Am 25:333–348 (1996).
• Tran, T. T., A. Medline, and W. R. Bruce. “Insulin promotion of colon tumors in rats.” Cancer Epidemiol Biomarkers Prev 5:1013–1015 (1996).
• Tsujii, M., S. Kawano, and R. N. DuBois. “Cyclooxygenase-2 expression inhuman colon cancer cells increases metastatic potential.” Proc Natl AcadSci U S A 94:3336–3340 (1997).
• Uefuji, K., T. Ichikura, and H. Mochizuki. “Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.” Clin Cancer Res 6:135–138 (2000).
• Vergote, I. B., P. A. van Dam, G. M. Laekeman, G. H. Keersmaeckers, F. L. Uyttenbroeck, and A. G. Herman. “Prostacyclin/thromboxane ratio in human breast cancer.” Tumour Biol 12:261–266 (1991).
• Welch, H. G., L. M. Schwartz, and S. Woloshin. “Are increasing 5-year survival rates evidence of success against cancer?” JAMA 283:2975–2978 (2000).
• Wen, B., E. Deutsch, P. Opolon, A. Auperin, V. Frascogna, E. Connault, and J. Bourhis. “n-3 polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionizing radiation with inhibition of tumour angiogenesis.” Br J Cancer 89:1102–1107 (2003).
• Wigmore, S. J., M. D. Barber, J. A. Ross, M. J. Tisdale, and K. C. Fearon. “Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer.” Nutr Cancer 36:177–814 (2000).
• Willams, C. S., M. Mann, and R. N. DuBois. “The role of cyclooxygenases in inflammation, cancer, and development.” Oncogene 18:7980–7916 (1999).
• Yam, D. “Insulin-cancer relationships. Possible dietary implications.” MedHypotheses38:111–117 (1992).
• Yam, D., A. Peled, and M. Shinitzky. “Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin.” Cancer Chemother Pharmacol 47:34–40 (2001).
• Yokoyama, I., S. Hayashi, T. Kobayashi, M. Negita, M. Yasutomi, K. Uchida, and H. Takagi. “Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor.” Res Exp Med (Berl) 195:209–215 (1995).
• Yoshikawa, T., Y. Noguchi, C. Doi, T. Makino, and K. Noruma. “Insulin resis-tance in patients with cancer: relationships with tumor site, tumor stage,body-weight loss, acute-phase response, and energy expenditure.” Nutri-tion 17:590–593 (2001).

• Adams, P., S. Lawson, A. Sanigorski, and A. J. Sinclair. “Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.” Lipids 31:S157–S161 (1996).
• Ahmann, P. A., S. J. Waltonen, K. A. Olson, F. W. Theye, A. J. van Erem, and R. J. LePlant. “Placebo-controlled evaluation of Ritalin side effects.” Pedi-atrics 91:1101–1106 (1993).Aisen, P. S. “Anti-inflammatory therapy for Alzheimer’s disease.” NeurobiolAging 21:447–448 (2000).Aisen, P. S. “Anti-inflammatory therapy for Alzheimer’s disease: implicationof the prednisone trial.” Acta Neurol Scand 176:85–89 (2000).
• Akiyama, H., T. Arai, H. Kondo, E. Tanno, C. Haga, and K. Ikeda. “Cell media-tors of inflammation in the Alzheimer disease brain.” Alzheimer Diseaseand Associated Disorders 14:S47–S53 (2000).
• Amen, D. G. Change Your Brain, Change Your Life. New York: Random House, 1998.
• Amen, D. G. Healing ADD. New York: G.P. Putnam, 2001.
• Bell, J.G., E. E. MacKinlay, J. R. Dick, D. J. MacDonald, R. M. Boyle, and A. C. Glen. “Essential fatty acids and phospholipase A(2) in autistic spectrum disorders.” Prostaglandins Leukot Essent Fatty Acids 71:201–204 (2004).
• Burdge, G. C., S. M. Wright, J. O. Warner, and A. D. Postle. “Fetal brain and liver phospholipids fatty acid composition in a guinea pig model of fetal alcohol syndrome: effect of maternal supplementation with tuna oil.” J Nutr Biochem 8:438–444 (1997).
• Burgress, J. R., L. Stevens, and L. Peck. “Long-chain polyunsaturated fattyacids in children with attention-deficit hyperactivity disorder.” Am J ClinNutr 71:327S-330S (2000).
• Bush, G., J. A. Frazier, S. L. Rauch, L. J. Seidman, P. J. Whalen, M. A. Jenike, B. R. Rosen, and J. Biederman. “Anterior cingulated cortex dysfuction in attention deficit/hyperactivity disorder revealed by fMRI and the counting stroop.” Biol Psychiatry 45:1542–1552 (1999).
• Calon, F., G. P. Lim, F. Yang, T. Morihara, B. Teter, O. Ubeda, P. Rostaing, A. Triller, N. Salem, K. H. Ashe, S. A. Frutschy, and G. M. Cole. “Docosahexaenoic acid protects for dendritic pathology in a Alzheimer’s disease mouse model.” Neuron 43:633–645 (2004).
• Carrie, I., M. Clement, D. De Javel, H. Frances, and J. M. Bourre. “Learning deficits in the first generation OF1 mice deficient in (n-3) polyunsaturated fatty acids do not result from visual alteration.” Neurosci Lett 266:69–72 (1999).
• Connor, W. E., M. Neuringer, and S. Reisbick. “Essential fatty acids: importance of n-3 fatty acids in the retina and brain.” Nutr Rev 50:21–29 (1992).
• Conquer, J. A., M. C. Tierney, J. Zecevic, W. J. Bettger, and R. H. Fisher. “Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment.” Lipids 35:1305–1312 (2000).
• Cooper, N. R., R. N. Kalaria, P. L. McGeer, and J. Rogers. “Key issues in Alzheimer’s disease inflammation.” Neurobiology Aging 21:451–453 (2000).
• Delion, S., S. Chalon, D. Guilloteau, J. C. Besnard, and G. Durand. “Alpha linolenic acid deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmitters in the rat frontal cortex.” J Neurochem 66:1582–1591 (1996).
• Delion, S., S. Chalon, J. Herault, D. Guilloteau, J. C. Besnard, and G. Durand. “Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmitters in rats.” J Nutr 124:2466–2476 (1994).
• Ensel, M., H. Milon, and A. Malnoe. “Effect of low intake of n-3 fatty acids during development of brain phospholipid, fatty acid composition and exploratory behavior in rats.” Lipids 26:203–208 (1991).
• Fenton, W. S., J. Hibbeln, and M. Knable. “Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia.” Biol Psychiatry 47:8–21 (2000).
• Fernstrom, J. D. “Effects of dietary polyunsaturated fatty acids on neuronal function.” Lipids 34:161–169 (1999).
• Freychet, P. “Insulin receptors and insulin actions in the nervous system.” Diabetes Metab Res Rev 16:390–392 (2000).
• Gayo, A., L. Mozo, A. Suarez, A. Tunon, C. Lahoz, and C. Gutierrez. “Inteferon beta treatment modulates TNF and interferon gamma spontaneous gene expression in MS.” Neurology 52:1764–1770 (1999).
• Gesch, C. B., S. M. Hammond, S. E. Hampson, A. Eves, and M. J. Crowder. “Influence of supplementary vitamins, minerals and essential fatty acids on the anti-social behavior of young adult prisoners.” Br J Psychiatry 181:22–28 (2002).
• Glueck, C. J., M. Tieger, R. Kunkel, T. Tracy, J. Speirs, P. Streicher, and E. Illig. “Improvement in symptoms of depression and in an index of life stressors accompany treatment of severe hypertriglyceridemia.” Biol Psychiatry 34:240–252 (1993).
• Hallahan, B. and M. R. Garland. “Essential fatty acids and their role in thetreatment of impulsivity disorders.” Prostaglandins Leukot Essent FattyAcids 71:211–216 (2004).
• Hallowell, E. and J. J. Ratey. Driven to Distraction. New York: Touchstone Books, 1995.
• Hamazaki, T. and S. Hirayama. “The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder—a placebo control double-blind study.” Eur J Clin Nutr 58:838 (2004).
• Hamazaki, T., S. Sawazaki, M. Itomura, E. Asaoka, Y. Nagao, N. Nishimura, K. Yazawa, T. Kuwamori, and M. Kobayashi. “The effect of docosahexaenoic acid on aggression in young adults.” JClin Invest97:1129–1134 (1996).
• Hamaszki, T., S. Sawazaki, M. Itomura, Y. Nagao, A. Thienprasert, T. Nagasawa, and S. Watanabe. “Effect of docosahexaenoic acid on hostility.” World Rev Nutr Diet 88:47–52 (2001).
• Hibbeln, J.R. “Fish consumption and major depression.” Lancet 351:1213 (1998).
• Hibbeln, J. R. “Seafood consumption and homicide mortality.” World Rev NutrDiet 88:41–46 (2001).
• Hibbeln, J. R. and N. Salem. “Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy.” Am J Clin Nutr 62:1–9 (1995).
• Hirayama, S., T. Hamazaki, and K. Terasawa. “Effect of docosahexaenoic acid -containing food administration on symptoms of attention-deficit/hyperactivity disorder—a placebo-controlled double-blind study.” Eur J Clin Nutr 58:467–473 (2004).
• Hohlfeld, R. and H. Wiendl. “The ups and downs of multiple sclerosis therapeutics.” Ann Neurol 49:281–284 (2001).
• Holden, R. J., I. S. Pakula, and P. A. Mooney. “The role of brain insulin in the neurophysiology of serious mental disorders: review.” Med Hypothesis 52:193–200 (1999).
• Hoozemans, J. J. M., A. J. M. Rozemuller, I. Janssen, C. J. A. De Groot, R. Veerhuls, and P. Eikelenboon. “Cyclooxygenase expression in microglia and neurons in Alzheimer’s disease and control brain.” Acta Neuropathol 101:2–8 (2001).
• Hoozemans, J. J. M., R. Veerhuis, I. Janssen, A. J. M. Rozemuler, and P. Eikelenboom. “Interleukin-1 beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neroblastoma cells: implications for Alzheimer’s disease.” Exp Gerontology 36:559–570 (2001).
• Horrobin, D. F. “Essential fatty acids, prostaglandins, and alcoholism: an overview.” Alcohol Clin Exp Res 11:2–9 (1987).
• Hunot, S., and E. C. Hirsch. “Neuroinflammatory processes in Parkinson’s disease.” Ann Neurol 53:S49–S60 (2003).
• Ikemoto, A., A. Nitta, S. Furukawa, M. Ohishi, A. Nakamure, Y. Fujii, and H. Okuyama. “Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus.” Neurosci Lett 285:99–102 (2000).
• Kademi, M., E. Wallstrom, M. Andersson, F. Piehl, R. Di Marco, and T. Olsson. “Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.” J Neurochem 103:202–210 (2000).
• Kalmijn, S., D. Foley, L. White, C. M. Burchfiel, J. D. Curb, H. Petrovitch, G. W.Ross, R. J. Havlik, and L. J. Launer. “Metabolic cardiovascular syndromeand risk of dementia in Japanese-American elderly men.” ArteriosclerThromb Vasc Biol 20:2255–2260 (2000).
• Kawas, C. H. and R. Brookmeyer. “Aging and the public health: effects of dementia.” N Engl J Med 344:1160–1161 (2001).
• Kyle, D. J., E. Schaefer, G. Patton, and A. Beiser. “Low serum docosahexaenoic acid is a significant risk factor for Alzheimer’s dementia.” Lipids 34:S245 (1999).
• Lauritzen, I., N. Blondeau, C. Heurteaux, C. Widmann, G. Romey, and M. Lazdunski. “Polyunsaturated fatty acids are potent neuroprotectors.” EMBO J 19:1784–1793 (2000).
• Maes, M. “Fatty acid composition in major depression: decreased n-3 fractions in cholesterol esters and increased C20:n6/C20:5n3 ratio in cholesterol ester and phospholipids.” J Affect Dis 38:35–46 (1996).
• Maes, M., A. Christophe, J. Delanghe, C. Altamura, H. Neels, and H. Y. Meltzer. “Lowered omega-3 polyunsaturated fatty acids in serum phospholpids and cholesteryl esters of depressed patients.” Psychiatry Res 85:275–291 (1999).
• Manev, H., U. Tolga, K. Sugaya, and T. Qu. “Putative role of neuronal 5 lipoxygenase in an aging brain.” FASEB J 14:1464–1469 (2000).
• Marcheselli, V. L., S. Hong, W. J. Lukiw, X. H. Tian, K. Gronert, A. Musto, M. Hardy, J. M. Gimenz, N. Chian, C. N. Serhan, and G. Bazan. “Novel docosanoids inhibit brain ischemia-reperfusion-mediate leukocyte infiltration and pro-inflammatory gene expression.” J Biol Chem 278:43807–43817 (2003).
• McGeer, P. L., E. G. McGeer, and K. Yasojima. “Alzheimer disease and neuroinflammation.” J Neural Transm 59:53–57 (2000).
• McGeer, P. L., M. Shulzer, and E. G. McGeer. “Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiological studies.” Neurology 47:425–432 (1996).
• Mills, D. E., K. M. Prkochin, K. A. Harvey, and R. P. Ward. “Dietary fatty acid sup-plementation alters stress reactivity and performance in man.” J HumanHypertension 3:111–116 (1989).
• Mischoulon, D. and M. Fava. “Docosahexanoic acid and omega-3 fatty acids in depression.” Psychiatr Clin North Am 23:785–794 (2000).
• Miyanga, K., K. Yonemura, T. Takagi, R. Kifune, Y. Kishi, F. Miyakawa, K. Yazawa, and Y. Shirota. “Clinical effects of DHA in demented patients.” J Clin Ther Med 11:881–901 (1995).
• Montine, T. J., K. R. Sidell, B. C. Crews, W. R. Markesbery, L. J. Marnett, L. J. Roberts, and J. D. Morrow. “Elevated CSF prostaglandin E2 levels in patients with probable AD.” Neurology 53:1495–1498 (1999).
• Moriguchi, T., R. S. Greiner, and N. Salem. “Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration.” J Neurochem 75:2563–2573 (2000).
• Morris, M. C., D. A. Evans, J. L. Bienias, C. C. Tangney, D. A. Bennett, R. S. Wilson, N. Aggarwal, and J. Schneider. “Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease.” Arch Neurol 60:940–966 (2003).
• Nagatsu, T., M. Mogi, H. Ichinose, and A. Togari. “Cytokines in Parkinson’s disease.” J Neural Transm 58:143–151 (2000).
• Nemets, B., Z. Stahl, and R. H. Belmaker. “Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.” Am J Psychiatry 159:477–479 (2002).
• Neuroinflammation Working Group. “Inflammation and Alzheimer’s disease.” Neurobiology Aging 21:383–421 (2000).
• Nightingale, S., E. Woo, A. D. Smith, J. M. French, M. M. Gale, H. M. Sinclair, D. Bates, and D. A. Shaw. “Red blood cell and adipose tissue fatty acids in active and inactive multiple sclerosis patients.” Acta Neurol Scand 82:43–50 (1990).
• Nordvik, I., K-M. Myhr, H. Nyland, and K. S. Bjerve. “Effect of dietary adviceand n-3 supplementation in newly diagnosed MS patients.” Acta NeurolScand 102:143–149 (2000).
• Pasinetti, G. M., and P. S. Aisen. “Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain.” Neuroscience 87:319–324 (1997).
• Pawlosky, R. J. and N. Salem. “Ethanol exposure causes a decrease in docosahexanenoic acid and an increase in docosapentaenoic acid in feline brain and retina.” Am J Clin Nutr 61:1284–1289 (1995).
• Peet, M. “Essential fatty acid deficiency in erthrocyte membranes from chronic schizophrenic patients and clinical effects of dietary supplementation.” Prostaglandins Leukot Essent Fatty Acids 55:71–75 (1996).
• Peet, M., J. Brind, C. N. Ramchand, S. Shah, and G. K. Vankar. “Two double blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.” Schizophr Res 49:243–251 (2001).
• Pratico, D. and J. Q. Rojanowski. “Inflammatory hypothesis: novel mechanisms of Alzheimer’s neurodegradation and new therapeutic targets?” Neurobiology Aging 21:441–445 (2000).
• Rasgon, N. and L. Jarvik. “Insulin resistance, affective disorders, and Alzheimer’s disease.” J Gerontology 59A:178–183 (2004).
• Reisbick, S., M. Neuringer, R. Hasnain, and W. E. Connor. “Home cage behaviorof rhesus monkey with long-term deficiency of omega-3 fatty acids.” Phys-iol Behav 55:231–239 (1994).
• Remarque, E. J., E. L. E. M. Bollen, A. W. E. Weverling-Rijnsburger, J. C. Laterveer, G. J. Blauw, and R. G. J. Westendorp. “Patients with Alzheimer’s disease display a pro-inflammatory phenotype.” Exp Gerontology 36:171–176 (2001).
• Richardson, A. J., C. M. Calvin, C. Clisby, D. R. Schoenheimer, P. Montgomery, J. A. Hall, G. Hebb, E. Westwood, J. B, Talcott, and J. F. Stein. “Fatty acid deficiency signs predict the severity of reading and related difficulties in dyslexic children.” Prostaglandins Leukot Essent Fatty Acids 63:69–74 (2000).
• Richardson, A. J. and B. K. Puri. “A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties.” Prog Neuropsychopharmacol Biol Psychiatry 26:233- 239 (2002).
• Richardson, A. J. and M. A. Ross. “Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum.” Prostaglandins Leukot Essent Fatty Acids 63:1-9 (2000).
• Ross, B. M., I. McKenzie, I. Glen, and C. P. Bennett. “Increased levels of ethane, a non-invasive marker of n- 3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder.” Nutr Neurosci 6:277–281 (2003).
• Sachdev, P. “Attention deficit hyperactivity disorder in adults.” Psychological Med 29:507–514 (1999).
• Sears, B. The Zone. New York: ReganBooks, 1995.
• Sears, B. TheAnti-Aging Zone. New York: ReganBooks, 1999.
• Sears, B. The Omega Rx Zone. New York: ReganBooks, 2002.
• Sonderberg, M., C. Edlund, K. Kristensson, and G. Dallner. “Fatty acid composition of brain phospholipids in aging and Alzheimer’s disease.” Lipids 26:421–423 (1991).
• Stein, J. “The neurobiology of reading difficulties.” Prostaglandins LeukotEssent Fatty Acids 63:109–116 (2000).
• Stevens, L. J. and J. Burgess. “Omega-3 fatty acids in boys with behavior, learning, and health problems.” Physiology Behavior 59:915–920 (1996).
• Stevens, L. J., S. S. Zentall, J. L. Deck, M. L. Abate, B. A. Watkins, S. A. Lipp, and J. R. Burgess. “Essential fatty acid metabolism in boys with attention deficit hyperactivity disorder.” Am J Clin Nutr 62:761–768 (1995).
• Stevens, L., W. Zhang, L. Peck, T. Kuczek, N. Grevstad, A. Mahon, S. S. Zentall, L. E. Arnold, and J. R. Burgess. “EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors.” Lipids 38:1007–1021 (2003).
• Stewart, W. F., C. Kawas, M. Corrada, and E. J. Metter. “Risk of Alzhemier’s disease and duration of NSAID use.” Neurology 48:626–632 (1997).
• Stoll, A. L., E. Sverus, M. P. Freeman, S. Rueter, H. A. Zhoyan, E. Diamond, K. K. Cress, and L. B. Marangell. “Omega-3 fatty acids in bipolar depression: a preliminary double-blind, placebo-controlled trial.” Arch Gen Psychiatry 56:407–412 (1999).
• Stordy, B. J. “Benefit of docosahexaenoic acid supplements to dark adaption in dyslexics.” Lancet346:385 (1995).
• Su, K. P., S. Y. Huang, C. C. Chiu, and W. W. Shen. “Omega-3 fatty acids in major depressive disorder.” Eur Neuropsychopharmacology 13:267–271 (2003).
• Tanskanen, A. “Fish consumption, depression, and suicidality in a general population.” Arch Gen Psychiatry 58:512–513 (2001).
• Taylor, K. E. and A. J. Richardson. “Visual function, fatty acids and dyslexia.” Prostglandins Leukot Essent Fatty Acids 63:89–93 (2000).
• Terano, T., S. Fujishiro, T. Ban, K. Ymamoto, T. Tanaka, Y. Noguchi, Y. Tamura, K. Yazawa, and T. Hirayama. “Docosahexaenoic acid supplementation improves moderately severe dementia from thrombotic cerebrovascular diseases.” Lipids 34:S345-S346 (1999).
• Teunissen, C. E., M. P. J. van Boxtel, H. Bosma, E. Bosmans, J. Delanghe, De Bruijin, A. Wauters, M. Maes, J. Jolles, H. W. M. Steinbusch, and J. de Vente. “Inflammatory markers in relation to cognition in a healthy aging population.” J Neuroimmunity 134:142–150 (2003).
• Tully, A., H. M. Roche, R. Doyle, C. Fallon, I. Bruce, B. Lawlor, D. Coakley, and M. J. Gibney. “Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease.” Br J Nutr 89:483–489 (2003).
• Uauy, R., P. Peirano, D. Hoffman, P. Mena, D. Birch, and E. Birch. “Role of essential fatty acids in the function of the developing nervous system.” Lipids 31:S167-S176 (1996).
• Venters, H. D., R. Dantzer, and K. W. Kelly. “A new concept in neurodegeneration: TNF is a silencer of survival signals.” Trends in Neuroscience 23:175–180 (2000).
• Virkkunen, M. E., D. F. Horrobin, K. Douglas, K. Jenkins, and M. S. Manku. “Plasma phospholipids essential fatty acids and prostaglandin in alcoholic, habitually violent, and impulsive offenders.” Biol Psychiatry 22:1087–1096 (1987).
• Vitkovic, L., J. Bockaert, and C. Jacque. “Inflammatory cytokines: neuromodulators in normal brain?” J Neurochem 74:457–471 (2000).
• Yehuda, S., S. Rabinovitz, R. L. Carasso, and D. I. Mostofsky. “Essential fattyacid preparation improves Alzheimer’s patients quality of life.” Int J Neu-rosci 87:141–149 (1996).
• Yehuda, S., S. Rabinovitz, and D. I. Mostofsky. “Essential fatty acids are mediators of brain biochemistry and cognitive functions.” J Neurosci Res 56:565–570 (1999).
• Zametkin, A. J., and M. Ernst. “Problems in the management of attention deficit-hyperactivity disorder.” N Engl J Med 340:40–46 (1999).
• Zametkin, A. J., T. E. Nordahl, A. C. King, W. E. Semple, J. Rumsey, S. Hamburger, and R. M. Cohen. “Cerebral glucose metabolism in adults with hyperactivity of childhood onset.” N Engl J Med 323:1361–1366 (1990).
• Zimmer, L., S. Hembert, G. Durand, P. Breton, D. Guillotau, J. C. Besnard, and S. Chalon. “Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex.” Neurosci Letter 240:177–181 (1998).
• Zimmer, L., S. Vancassel, S. Cantagrel, P. Breton, S. Delamanche, D. Guil-loteau, G. Durand, and S. Chalon. “The dopamine mesocorticolimbic path-way is affected by deficiency in n-3 polyunsaturated fatty acids.” Am JClin Nutr 75:662–667 (2002).

• Adam, O., C. Beringer, T. Kless, C. Lemmen, A. Adam, M. Wiseman, P. Adam, R. Klimmek, and W. Forth. “Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis.” Rheumatol Int 23:27–36 (2003).
• Ariza-Ariza, R., M. Mestanza-Peralta, and M. H. Cardiel. “Omega-3 fatty acids in rheumatoid arthritis: an overview.” Semin Arthritis Rheum 27:366–370 (1998).
• Babcok, T., W. S. Helton, and N. J. Espat. “Eicosapentaenoic acid: an anti inflammatory omega-3 fat with potential clinical applications.” Nutrition 16:1116–1118 (2000).
• Belluzzi, A., S. Boschi, C. Brignola, A. Munarini, G. Cariani, and F. Miglio.“Polyunsaturated fatty acids and inflammatory bowel disease.” Am J ClinNutr 71:339S-42S (2000).
• Belluzzi, A., C. Brignola, M. Campieri, A. Pera, S. Boschi, and M. Miglioli. “Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease.” N Engl J Med 354:1557–1560 (1996).
• Blok, W. L., M. B. Katan, and J. W. van der Meer. “Modulation of inflammation and cytokine production by dietary (n-3) fatty acids.” J Nutr 126:1515–1533 (1996).
• Calder, P. C. “n-3 polyunsaturated fatty acids and cytokine production in health and disease.” Ann Nutr Metab 41:203–234 (1997).
• Calder, P. C. “n-3 polyunsaturated fatty acids, inflammation and immunity.” Nutr Res 21:309–341 (2001).
• Chandrasekar, B., and G. Fernandes. “Decreased pro-inflammatory cytokines and increased antioxidant enzyme gene expression by omega-3 lipids in murine lupus nephritis.” Biochem Biophys Res Commun 200(2):893–898 (1994).
• Clark, W. F., A. Parbtani, C. D. Naylor, C. M. Levinton, N. Muirhead, E. Spanner, M. W. Huff, D. J. Philbrick, and B. J. Holub. “Fish oil in lupus nephritis: clinical findings and methodological implications.” Kidney Int 44:75–86 (1993).
• Cleland, L. G., J. K. French, W. H. Betts, G. A. Murphy, and M. J. Elliot. “Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis.” J Rheumatol 15:1471–1475 (1988).
• Das, U. N. “Beneficial effects of eicosapentaenoic and docosahexaenoic acids in the management of systemic erthematosus and its relationship to the cytokine network.” Prostaglandins Leukot Essent Fatty Acids 51:207–213 (1994).
• Donadio, J. V., J. P. Grande, E. J. Bergstralh, R. A. Dart, T. S. Larson, and D. C. Spencer. “The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial.” J Am Soc Nephrol 10:1772–1777 (1999).
• Endres, S. “Messengers and mediators: interactions among lipids, eicosanoids, and cytokines.” Am J Clin Nutr 57:798S–800S (1993).
• Endres, S. “n-3 polyunsaturated fatty acids and human cytokine synthesis.” Lipids 31 S239–S242 (1996).
• Endres, S., R. Ghorbani, V. E. Kelley, K. Georgilis, G. Lonnemann, J. W. van der Meer, J. G. Cannon, T. S. Rogers, M.S. Klempner, and P.C. Weber. “The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells.” N Engl J Med 320:265–271 (1989).
• Endres, S., R. Lorenz, and K. Loeschke.”Lipid treatment of inflammatory bowel disease.” Curr Opin Clin Nutr Metab Care 2:117–120 (1999).
• Endres, S., B. Sinha, and T. Eisenhut. “Omega 3 fatty acids in the regulation of cytokine synthesis.” World Rev Nutr Diet 76:89–94 (1994).
• Endres, S., and C. von Schacky. “n-3 polyunsaturated fatty acids and human cytokine synthesis.” Curr Opin Lipidol 7:48–52 (1996).
• Fox, D. A. “Cytokine blockade as a new strategy to treat rheumatoid arthritis. Inhibition of tumor necrosis factor.” Arch Intern Med 160:437–444 (2000).
• Geusens, P., C. Wouters, J. Nijs, Y. Jiang, and J. Dequeker. “Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study.” Arthritis Rheum 37:824–829 (1994).
• Kilkens, T. O. C., A. Honig, M. Maes, R. Lousberg, and R. J. Brummer. “Fatty acid profile and affective dysregulation in irritable bowel syndrome.” Lipids 39:425–431 (2004).
• Kremer, J. M. “N-3 fatty acid supplements in rheumatoid arthritis.” Am J Clin Nutr 71:349S–351S. (2000).
• Kremer, J. M., D. A. Lawrence, G. F. Petrillo, L. L. Litts, P. M. Mullaly, R. I.Rynes, R. P. Stocker, N. Parhami, N. S. Greenstein, and B. R. Fuchs.“Effects of high-dose fish oil on rheumatoid arthritis after stopping nons-teroidal antiinflammatory drugs. Clinical and immune correlates.” ArthritisRheum 38:1107–1114 (1995).
• Lo, C. J., K. C. Chiu, M. Fu, R. Lo, and S. Helton. “Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappaB activity.” J Surg Res 82:216–221 (1999).
• Meydani, S. N. “Effect of n-3 polyunsaturated fatty acid on cytokine production and their biological action.” Nutrition 12:S8–14 (1996).
• Ozgocmen, S., S. A. Catal, O. Ardicoglu, and A. Kamanli. “Effect of omega-3fattyacids in the management of fibromyalgia syndrome.” Int J Clin Phar-macol Ther 38:362–363 (2000).
• Pisetsky, D. S. “Tumor necrosis factor blockers in rheumatoid arthritis.” N Engl J Med 342:810–811 (2000).
• Prickett, J. D., D. R. Robinson, and A. D. Steinberg. “Dietary enrichment with polyunsaturated acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZBxNZW F1 mice.” JClin Invest68:556–559 (1981).
• Robinson, D. R., L. L. Xu, S. Tateno, M. Guo, and R. B. Colvin. “Suppression of autoimmune disease by dietary n-3 fatty acids.” J Lipid Res 34:1435–1444 (1993).
• Ross, E. “The role of marine oils in the treatment of ulcerative colitis.” Nutr Rev 51:47–49 (1993).
• Shapiro, H. “Could n-3 polyunsaturated fatty acids reduce pathological paindirect actions on the nervous system.” Prostaglandins Leukot EssentFatty Acids 68:219–224 (2003).
• Simopoulos, A. P. “Omega-3 fatty acids in inflammation and autoimmune diseases.” J Am Coll Nutr 21:495–505 (2002).
• Sperling, R. I. “The effects of dietary n-3 polyunsaturated fatty acids on neutrophils.” Proc Nutr Soc 57:527–534 (1998).
• Teitelbaum, J. E. and W. Allan Walker. “The role of omega 3 fatty acids in intestinal inflammation.” J Nutr Biochem 12:21–32 (2001).
• Wolfe, F., K. Ross, J. Anderson, I. J. Russel, and L. Hebert. “The prevalenceand characteristics of fibromyalgia in the general population.” ArthritisRheum 38:19–28 (1995).
• Zaloga, G. P. and P. Parik. “Lipid modulation and systemic inflammation.” CritCare Clin17:201–217.
• Zurier, R. B. “Prostaglandins, immune responses and murine lupus.” ArthRheum 25:804–809 (1982).
• Zurier, R. B. “Lipids and lupus.” In Lupus: Molecular and Cellular Pathogenesis, ed. G. M. Kammer and G. C. Tsokos, pp. 599–611, Totowan, N.J.: Humana Press, 1998.

• Darman, N., A. Briend, and A. Drewnowski. “Energy-dense diets are associated with lower diet costs.” Public Health Nutrition 7:21–27 (2004).
• Drewnowski, A. “Energy density, palatability and satiation: implications for weight control.” Nutr Rev 56:347–353 (1998).
• Drewnowski, A. “Fat and sugar: an economic analysis.” J Nutr 133:838S 840S (2003).
• Drewnowski, A. “The role of energy density.” Lipids 38:109–115 (2003).
• Nestle, M. Food Politics. How the Food Industry Influences Nutrition andHealth. Berkeley, CA: University of California Press, 2002.
• Nestle, M. “The ironic politics of obesity.” Science 299:781 (2003).
• Nielsen, S. J., and B. M. Popkin. “Patterns and trends in food portion sizes, 1977–1998.” JAMA 289:450–453 (2003).
• Popkin, B. M. and S. J. Nielsen. “The sweetening of the world’s diet.” ObesityRes 11:1325–1331 (2003).

• Noakes, M., P. R. Foster, J. B. Keogh, and P. M. Clifton. “Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome.” J Nutr 134:1894–1899 (2004).
• Willet, W. C. Eat, Drink and Be Healthy. The Harvard Medical School Guide toHealthy Eating. New York: Fireside, 2001.
• Yao, M. and S. B. Roberts. “Dietary energy density and weight regulation.” Nutr Rev 59:247–258 (2001).

Presidente, Inflammation Research Foundation, Marblehead, Massachusetts...

La Dieta de la Zona es un estilo de vida saludable que se caracteriza por alcanzar un correcto equilibrio hormonal...

Los alimentos se clasifican en función de su contenido mayoritario de nutrientes...

Los ácidos grasos omega 3 son esenciales para la vida y nuestro organismo no es capaz de sintetizarlos, por ello debemos consumirlos diariamente...

Para calcular qué debemos comer cada día, o lo que es lo mismo, cuál es nuestro número de bloques, se debe tener en cuenta el porcentaje de grasa corporal, de masa magra y la actividad física que realizamos entre otros factores...

La Dieta de la Zona permite conseguir los siguientes beneficios para la salud...

Snacks salados y Cremas
Tentempiés salados 40-30-30
Crema de Verduras 40-30-30
Crema de Setas 40-30-30

Batidos y Proteínas
Instant Meal 40-30-30
EnerZona Soja 90%
EnerZona Whey 90% (suero de leche)